1-1	0-8	Bayesian	_	_
1-2	9-22	computational	_	_
1-3	23-30	markers	_	_
1-4	31-33	of	_	_
1-5	34-41	relapse	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-6	42-44	in	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-7	45-60	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
1-8	61-71	dependence	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-9	72-87	Methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-10	88-91	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-11	92-100	disorder	_	_
1-12	101-103	is	_	_
1-13	104-114	associated	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-14	115-119	with	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-15	120-121	a	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-16	122-126	high	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-17	127-137	likelihood	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-18	138-140	of	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-19	141-148	relapse	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-20	148-149	.	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse

2-1	150-161	Identifying	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
2-2	162-168	robust	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
2-3	169-179	predictors	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
2-4	180-182	of	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
2-5	183-190	relapse	_	_
2-6	191-195	that	_	_
2-7	196-200	have	_	_
2-8	201-212	explanatory	_	_
2-9	213-218	power	_	_
2-10	219-221	is	_	_
2-11	222-230	critical	_	_
2-12	231-233	to	_	_
2-13	234-241	develop	_	_
2-14	242-251	secondary	_	_
2-15	252-262	prevention	_	_
2-16	263-268	based	_	_
2-17	269-271	on	_	_
2-18	272-273	a	_	_
2-19	274-285	mechanistic	_	_
2-20	286-299	understanding	_	_
2-21	300-302	of	_	_
2-22	303-310	relapse	_	_
2-23	310-311	.	_	_

3-1	312-325	Computational	_	_
3-2	326-336	approaches	_	_
3-3	337-341	have	_	_
3-4	342-345	the	_	_
3-5	346-355	potential	_	_
3-6	356-358	to	_	_
3-7	359-367	identify	_	_
3-8	368-372	such	_	_
3-9	373-383	predictive	_	_
3-10	384-391	markers	_	_
3-11	392-394	of	_	_
3-12	395-406	psychiatric	_	_
3-13	407-414	illness	_	_
3-14	414-415	,	_	_
3-15	416-420	with	_	_
3-16	421-424	the	_	_
3-17	425-434	advantage	_	_
3-18	435-437	of	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-19	438-447	providing	_	_
3-20	448-449	a	_	_
3-21	450-455	finer	_	_
3-22	456-467	mechanistic	_	_
3-23	468-479	explanation	_	_
3-24	480-482	of	_	_
3-25	483-486	the	_	_
3-26	487-496	cognitive	_	_
3-27	497-506	processes	_	_
3-28	507-517	underlying	_	_
3-29	518-529	psychiatric	_	_
3-30	530-543	vulnerability	_	_
3-31	543-544	.	_	_

4-1	545-547	In	_	_
4-2	548-552	this	_	_
4-3	553-558	study	_	_
4-4	558-559	,	_	_
4-5	560-569	sixty-two	_	_
4-6	570-578	recently	_	_
4-7	579-584	sober	_	_
4-8	585-610	methamphetamine-dependent	_	_
4-9	611-622	individuals	_	_
4-10	623-627	were	_	_
4-11	628-637	recruited	_	_
4-12	638-642	from	_	_
4-13	643-644	a	_	_
4-14	645-647	28	_	_
4-15	647-648	-	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-16	648-651	day	_	_
4-17	652-661	inpatient	_	_
4-18	662-671	treatment	_	_
4-19	672-679	program	_	_
4-20	679-680	,	_	_
4-21	681-684	and	_	_
4-22	685-694	completed	_	_
4-23	695-696	a	_	_
4-24	697-701	Stop	_	_
4-25	702-708	Signal	_	_
4-26	709-713	Task	_	_
4-27	714-715	(	_	_
4-28	715-718	SST	_	_
4-29	718-719	)	_	_
4-30	720-725	while	_	_
4-31	726-736	undergoing	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
4-32	737-747	functional	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
4-33	748-756	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
4-34	757-766	resonance	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
4-35	767-774	imaging	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
4-36	775-776	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-37	776-780	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-38	780-781	)	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-39	781-782	.	_	_

5-1	783-788	These	_	_
5-2	789-800	individuals	_	_
5-3	801-805	were	_	_
5-4	806-819	prospectively	_	_
5-5	820-828	followed	_	_
5-6	829-832	for	_	_
5-7	833-834	1	_	_
5-8	834-835	â€¯	_	_
5-9	835-839	year	_	_
5-10	840-843	and	_	_
5-11	844-852	assessed	_	_
5-12	853-856	for	_	_
5-13	857-864	relapse	_	_
5-14	865-867	to	_	_
5-15	868-883	methamphetamine	_	_
5-16	884-887	use	_	_
5-17	887-888	.	_	_

6-1	889-901	Thirty-three	_	_
6-2	902-909	percent	_	_
6-3	910-912	of	_	_
6-4	913-921	followed	_	_
6-5	922-934	participants	_	_
6-6	935-943	reported	_	_
6-7	944-951	relapse	_	_
6-8	951-952	.	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_

7-1	953-955	We	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-2	956-961	found	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-3	962-966	that	_	_
7-4	967-973	neural	_	_
7-5	974-982	activity	_	_
7-6	983-993	associated	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-7	994-998	with	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-8	999-1002	two	_	_
7-9	1003-1008	types	_	_
7-10	1009-1011	of	_	_
7-11	1012-1020	Bayesian	_	_
7-12	1021-1031	prediction	_	_
7-13	1032-1037	error	_	_
7-14	1037-1038	,	_	_
7-15	1039-1042	i.e	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
7-16	1042-1043	.	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
7-17	1044-1047	the	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
7-18	1048-1058	difference	_	_
7-19	1059-1066	between	_	_
7-20	1067-1073	actual	_	_
7-21	1074-1077	and	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-22	1078-1086	expected	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-23	1087-1091	need	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-24	1092-1094	to	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-25	1095-1099	stop	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-26	1100-1102	on	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-27	1103-1104	a	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-28	1105-1110	given	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-29	1111-1116	trial	_	_
7-30	1116-1117	,	_	_
7-31	1118-1131	significantly	_	_
7-32	1132-1146	differentiated	_	_
7-33	1147-1152	those	_	_
7-34	1153-1164	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-35	1165-1168	who	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
7-36	1169-1177	remained	_	_
7-37	1178-1187	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
7-38	1188-1191	and	_	_
7-39	1192-1197	those	_	_
7-40	1198-1201	who	_	_
7-41	1202-1210	relapsed	_	_
7-42	1210-1211	.	_	_

8-1	1212-1224	Specifically	_	_
8-2	1224-1225	,	_	_
8-3	1226-1234	relapsed	_	_
8-4	1235-1246	individuals	_	_
8-5	1247-1256	exhibited	_	_
8-6	1257-1264	smaller	_	_
8-7	1265-1271	neural	_	_
8-8	1272-1283	activations	_	_
8-9	1284-1286	to	_	_
8-10	1287-1291	such	_	_
8-11	1292-1300	Bayesian	_	_
8-12	1301-1311	prediction	_	_
8-13	1312-1318	errors	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
8-14	1319-1327	relative	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
8-15	1328-1330	to	_	_
8-16	1331-1336	those	_	_
8-17	1337-1348	individuals	_	_
8-18	1349-1352	who	_	_
8-19	1353-1361	remained	_	_
8-20	1362-1371	abstinent	_	_
8-21	1372-1374	in	_	_
8-22	1375-1378	the	_	_
8-23	1379-1383	left	_	_
8-24	1384-1399	temporoparietal	_	_
8-25	1400-1408	junction	_	_
8-26	1409-1410	(	_	_
8-27	1410-1417	Cohen's	_	_
8-28	1418-1419	d	_	_
8-29	1419-1420	â€¯	_	_
8-30	1420-1421	=	_	_
8-31	1421-1422	â€¯	_	_
8-32	1422-1426	0.91	_	_
8-33	1426-1427	)	_	_
8-34	1427-1428	,	_	_
8-35	1429-1432	the	_	_
8-36	1433-1437	left	_	_
8-37	1438-1446	inferior	_	_
8-38	1447-1454	frontal	_	_
8-39	1455-1460	gyrus	_	_
8-40	1461-1462	(	_	_
8-41	1462-1469	Cohen's	_	_
8-42	1470-1471	d	_	_
8-43	1471-1472	â€¯	_	_
8-44	1472-1473	=	_	_
8-45	1473-1474	â€¯	_	_
8-46	1474-1478	0.57	_	_
8-47	1478-1479	)	_	_
8-48	1479-1480	,	_	_
8-49	1481-1484	and	_	_
8-50	1485-1489	left	_	_
8-51	1490-1498	anterior	_	_
8-52	1499-1505	insula	_	_
8-53	1506-1507	(	_	_
8-54	1507-1514	Cohen's	_	_
8-55	1515-1516	d	_	_
8-56	1516-1517	â€¯	_	_
8-57	1517-1518	=	_	_
8-58	1518-1519	â€¯	_	_
8-59	1519-1523	0.63	_	_
8-60	1523-1524	)	_	_
8-61	1524-1525	.	_	_

9-1	1526-1528	In	_	_
9-2	1529-1537	contrast	_	_
9-3	1537-1538	,	_	_
9-4	1539-1548	abstinent	_	_
9-5	1549-1552	and	_	_
9-6	1553-1561	relapsed	_	_
9-7	1562-1574	participants	_	_
9-8	1575-1578	did	_	_
9-9	1579-1582	not	_	_
9-10	1583-1589	differ	_	_
9-11	1590-1592	in	_	_
9-12	1593-1599	neural	_	_
9-13	1600-1610	activation	_	_
9-14	1611-1613	to	_	_
9-15	1614-1623	non-model	_	_
9-16	1624-1629	based	_	_
9-17	1630-1634	task	_	_
9-18	1635-1644	contrasts	_	_
9-19	1645-1647	or	_	_
9-20	1648-1650	on	_	_
9-21	1651-1658	various	_	_
9-22	1659-1670	self-report	_	_
9-23	1671-1679	clinical	_	_
9-24	1680-1688	measures	_	_
9-25	1688-1689	.	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_

10-1	1690-1692	In	_	_
10-2	1693-1703	conclusion	_	_
10-3	1703-1704	,	_	_
10-4	1705-1713	Bayesian	_	_
10-5	1714-1723	cognitive	_	_
10-6	1724-1730	models	_	_
10-7	1731-1734	may	_	_
10-8	1735-1739	help	_	_
10-9	1740-1748	identify	_	_
10-10	1749-1759	predictive	_	_
10-11	1760-1770	biomarkers	_	_
10-12	1771-1773	of	_	_
10-13	1774-1781	relapse	_	_
10-14	1781-1782	,	_	_
10-15	1783-1788	while	_	_
10-16	1789-1798	providing	_	_
10-17	1799-1800	a	_	_
10-18	1801-1814	computational	_	_
10-19	1815-1826	explanation	_	_
10-20	1827-1829	of	_	_
10-21	1830-1836	belief	_	_
10-22	1837-1847	processing	_	_
10-23	1848-1851	and	_	_
10-24	1852-1860	updating	_	_
10-25	1861-1869	deficits	_	_
10-26	1870-1872	in	_	_
10-27	1873-1884	individuals	_	_
10-28	1885-1889	with	_	_
10-29	1890-1905	methamphetamine	_	_
10-30	1906-1909	use	_	_
10-31	1910-1918	disorder	_	_
10-32	1918-1919	.	_	_

11-1	1920-1930	Highlights	_	_
11-2	1931-1956	Methamphetamine-dependent	_	_
11-3	1957-1968	individuals	_	_
11-4	1969-1970	(	_	_
11-5	1970-1973	MDI	_	_
11-6	1973-1974	)	_	_
11-7	1975-1979	face	_	_
11-8	1980-1981	a	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
11-9	1982-1986	high	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
11-10	1987-1991	rate	_	_
11-11	1992-1994	of	_	_
11-12	1995-2002	relapse	_	_
11-13	2003-2008	after	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
11-14	2009-2018	treatment	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
11-15	2018-2019	.	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus

12-1	2020-2023	Can	_	_
12-2	2024-2025	a	_	_
12-3	2026-2034	Bayesian	_	_
12-4	2035-2043	learning	_	_
12-5	2044-2052	modeling	_	_
12-6	2053-2056	and	_	_
12-7	2057-2061	fMRI	_	_
12-8	2062-2064	be	_	_
12-9	2065-2069	used	_	_
12-10	2070-2072	to	_	_
12-11	2073-2081	identify	_	_
12-12	2082-2089	markers	_	_
12-13	2090-2092	of	_	_
12-14	2093-2100	relapse	_	_
12-15	2100-2101	?	_	_

13-1	2102-2105	MDI	_	_
13-2	2106-2109	who	_	_
13-3	2110-2118	relapsed	_	_
13-4	2119-2125	within	_	_
13-5	2126-2127	1	_	_
13-6	2127-2128	â€¯	_	_
13-7	2128-2132	year	_	_
13-8	2133-2137	have	_	_
13-9	2138-2145	smaller	_	_
13-10	2146-2156	activation	_	_
13-11	2157-2159	to	_	_
13-12	2160-2168	Bayesian	_	_
13-13	2169-2180	model-based	_	_
13-14	2181-2191	prediction	_	_
13-15	2192-2198	errors	_	_
13-16	2198-2199	.	_	_

14-1	2200-2204	Such	_	_
14-2	2205-2211	neural	_	_
14-3	2212-2219	pattern	_	_
14-4	2220-2223	was	_	_
14-5	2224-2232	observed	_	_
14-6	2233-2235	in	_	_
14-7	2236-2240	left	_	_
14-8	2241-2257	temporo-parietal	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
14-9	2258-2266	junction	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
14-10	2266-2267	,	_	_
14-11	2268-2271	IFG	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
14-12	2271-2272	,	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
14-13	2273-2276	and	_	_
14-14	2277-2285	anterior	_	_
14-15	2286-2292	insula	_	_
14-16	2292-2293	.	_	_

15-1	2294-2297	MDI	_	_
15-2	2298-2302	more	_	_
15-3	2303-2309	likely	_	_
15-4	2310-2312	to	_	_
15-5	2313-2320	relapse	_	_
15-6	2321-2325	show	_	_
15-7	2326-2332	weaker	_	_
15-8	2333-2341	tracking	_	_
15-9	2342-2344	of	_	_
15-10	2345-2356	uncertainty	_	_
15-11	2357-2360	and	_	_
15-12	2361-2369	updating	_	_
15-13	2370-2372	of	_	_
15-14	2373-2378	their	_	_
15-15	2379-2385	belief	_	_
15-16	2386-2391	model	_	_
15-17	2391-2392	.	_	_
























39-1	8182-8189	Methods	_	_
39-2	8190-8202	Participants	_	_
39-3	8203-8206	The	_	_
39-4	8207-8212	study	_	_
39-5	8213-8221	protocol	_	_
39-6	8222-8225	was	_	_
39-7	8226-8234	approved	_	_
39-8	8235-8237	by	_	_
39-9	8238-8241	the	_	_
39-10	8242-8246	UCSD	_	_
39-11	8247-8252	Human	_	_
39-12	8253-8261	Research	_	_
39-13	8262-8273	Protections	_	_
39-14	8274-8281	Program	_	_
39-15	8282-8285	and	_	_
39-16	8286-8289	all	_	_
39-17	8290-8298	subjects	_	_
39-18	8299-8303	gave	_	_
39-19	8304-8311	written	_	_
39-20	8312-8320	informed	_	_
39-21	8321-8328	consent	_	_
39-22	8328-8329	.	_	_

40-1	8330-8339	Sixty-two	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
40-2	8340-8341	(	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
40-3	8341-8344	21%	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
40-4	8345-8351	female	_	_
40-5	8351-8352	)	_	_
40-6	8353-8361	recently	_	_
40-7	8362-8367	sober	_	_
40-8	8368-8393	methamphetamine-dependent	_	_
40-9	8394-8405	individuals	_	_
40-10	8406-8410	were	_	_
40-11	8411-8420	recruited	_	_
40-12	8421-8425	from	_	_
40-13	8426-8427	a	_	_
40-14	8428-8430	28	_	_
40-15	8430-8431	-	_	_
40-16	8431-8434	day	_	_
40-17	8435-8444	inpatient	_	_
40-18	8445-8452	Alcohol	_	_
40-19	8453-8456	and	_	_
40-20	8457-8461	Drug	_	_
40-21	8462-8471	Treatment	_	_
40-22	8472-8479	Program	_	_
40-23	8480-8482	at	_	_
40-24	8483-8486	the	_	_
40-25	8487-8495	Veterans	_	_
40-26	8496-8503	Affairs	_	_
40-27	8504-8507	San	_	_
40-28	8508-8513	Diego	_	_
40-29	8514-8524	Healthcare	_	_
40-30	8525-8531	System	_	_
40-31	8532-8535	and	_	_
40-32	8536-8543	Scripps	_	_
40-33	8544-8549	Green	_	_
40-34	8550-8558	Hospital	_	_
40-35	8559-8560	(	_	_
40-36	8560-8562	La	_	_
40-37	8563-8568	Jolla	_	_
40-38	8568-8569	,	_	_
40-39	8570-8572	CA	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
40-40	8572-8573	;	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
40-41	8574-8589	cross-sectional	_	_
40-42	8590-8598	analysis	_	_
40-43	8599-8601	of	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
40-44	8602-8607	these	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
40-45	8608-8612	data	_	_
40-46	8613-8622	published	_	_
40-47	8623-8632	elsewhere	_	_
40-48	8632-8633	)	_	_
40-49	8633-8634	.	_	_

41-1	8635-8638	All	_	_
41-2	8639-8644	study	_	_
41-3	8645-8655	procedures	_	_
41-4	8655-8656	,	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
41-5	8657-8666	including	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
41-6	8667-8670	the	_	_
41-7	8671-8683	neuroimaging	_	_
41-8	8684-8691	session	_	_
41-9	8692-8701	examining	_	_
41-10	8702-8707	brain	_	_
41-11	8708-8711	and	_	_
41-12	8712-8720	behavior	_	_
41-13	8721-8730	responses	_	_
41-14	8731-8737	during	_	_
41-15	8738-8741	the	_	_
41-16	8742-8745	SST	_	_
41-17	8745-8746	,	_	_
41-18	8747-8755	occurred	_	_
41-19	8756-8762	during	_	_
41-20	8763-8766	the	_	_
41-21	8767-8772	third	_	_
41-22	8773-8775	or	_	_
41-23	8776-8782	fourth	_	_
41-24	8783-8787	week	_	_
41-25	8788-8790	of	_	_
41-26	8791-8800	treatment	_	_
41-27	8801-8804	for	_	_
41-28	8805-8808	all	_	_
41-29	8809-8821	participants	_	_
41-30	8822-8823	(	_	_
41-31	8823-8826	i.e	_	_
41-32	8826-8827	.	_	_
41-33	8827-8828	,	_	_
41-34	8829-8832	all	_	_
41-35	8833-8836	had	_	_
41-36	8837-8841	been	_	_
41-37	8842-8851	abstinent	_	_
41-38	8852-8856	from	_	_
41-39	8857-8872	methamphetamine	_	_
41-40	8873-8875	or	_	_
41-41	8876-8879	any	_	_
41-42	8880-8885	other	_	_
41-43	8886-8891	drugs	_	_
41-44	8891-8892	,	_	_
41-45	8893-8902	including	_	_
41-46	8903-8910	alcohol	_	_
41-47	8910-8911	,	_	_
41-48	8912-8915	for	_	_
41-49	8916-8917	3	_	_
41-50	8917-8918	â€“	_	_
41-51	8918-8919	4	_	_
41-52	8919-8920	â€¯	_	_
41-53	8920-8925	weeks	_	_
41-54	8925-8926	)	_	_
41-55	8926-8927	.	_	_

42-1	8928-8930	To	_	_
42-2	8931-8939	maintain	_	_
42-3	8940-8948	sobriety	_	_
42-4	8949-8955	during	_	_
42-5	8956-8959	the	_	_
42-6	8960-8967	program	_	_
42-7	8967-8968	,	_	_
42-8	8969-8981	participants	_	_
42-9	8982-8986	were	_	_
42-10	8987-8995	screened	_	_
42-11	8996-8999	for	_	_
42-12	9000-9003	the	_	_
42-13	9004-9012	presence	_	_
42-14	9013-9015	of	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
42-15	9016-9021	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
42-16	9022-9025	via	_	_
42-17	9026-9032	random	_	_
42-18	9033-9038	urine	_	_
42-19	9039-9049	toxicology	_	_
42-20	9050-9052	or	_	_
42-21	9053-9061	whenever	_	_
42-22	9062-9066	they	_	_
42-23	9067-9071	left	_	_
42-24	9072-9075	the	_	_
42-25	9076-9084	facility	_	_
42-26	9084-9085	,	_	_
42-27	9086-9089	and	_	_
42-28	9090-9094	were	_	_
42-29	9095-9105	terminated	_	_
42-30	9106-9110	from	_	_
42-31	9111-9114	the	_	_
42-32	9115-9122	program	_	_
42-33	9123-9125	if	_	_
42-34	9126-9132	tested	_	_
42-35	9133-9141	positive	_	_
42-36	9141-9142	.	_	_

43-1	9143-9155	Participants	_	_
43-2	9156-9160	also	_	_
43-3	9161-9170	performed	_	_
43-4	9171-9174	the	_	_
43-5	9175-9180	North	_	_
43-6	9181-9189	American	_	_
43-7	9190-9195	Adult	_	_
43-8	9196-9203	Reading	_	_
43-9	9204-9208	Test	_	_
43-10	9209-9211	as	_	_
43-11	9212-9213	a	_	_
43-12	9214-9221	measure	_	_
43-13	9222-9224	of	_	_
43-14	9225-9231	verbal	_	_
43-15	9232-9244	intelligence	_	_
43-16	9244-9245	,	_	_
43-17	9246-9249	and	_	_
43-18	9250-9259	completed	_	_
43-19	9260-9271	self-report	_	_
43-20	9272-9280	measures	_	_
43-21	9281-9283	of	_	_
43-22	9284-9295	personality	_	_
43-23	9296-9299	and	_	_
43-24	9300-9309	affective	_	_
43-25	9310-9318	measures	_	_
43-26	9319-9329	previously	_	_
43-27	9330-9340	associated	_	_
43-28	9341-9345	with	_	_
43-29	9346-9355	stimulant	_	_
43-30	9356-9365	addiction	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
43-31	9366-9379	vulnerability	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
43-32	9379-9380	,	_	_
43-33	9381-9390	including	_	_
43-34	9391-9394	the	_	_
43-35	9395-9402	Barratt	_	_
43-36	9403-9416	Impulsiveness	_	_
43-37	9417-9422	Scale	_	_
43-38	9423-9424	(	_	_
43-39	9424-9427	BIS	_	_
43-40	9427-9428	-	_	_
43-41	9428-9430	11	_	_
43-42	9430-9431	)	_	_
43-43	9431-9432	,	_	_
43-44	9433-9436	the	_	_
43-45	9437-9446	Sensation	_	_
43-46	9447-9454	Seeking	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
43-47	9455-9460	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
43-48	9461-9462	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
43-49	9462-9467	SSS-V	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
43-50	9467-9468	)	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
43-51	9468-9469	,	_	_
43-52	9470-9473	and	_	_
43-53	9474-9477	the	_	_
43-54	9478-9482	Beck	_	_
43-55	9483-9493	Depression	_	_
43-56	9494-9503	Inventory	_	_
43-57	9504-9505	(	_	_
43-58	9505-9508	BDI	_	_
43-59	9508-9509	)	_	_
43-60	9509-9510	.	_	_

44-1	9511-9519	Lifetime	_	_
44-2	9520-9526	DSM-IV	_	_
44-3	9527-9531	Axis	_	_
44-4	9532-9533	I	_	_
44-5	9534-9537	and	_	_
44-6	9538-9540	II	_	_
44-7	9541-9550	diagnoses	_	_
44-8	9551-9553	at	_	_
44-9	9554-9562	baseline	_	_
44-10	9563-9567	were	_	_
44-11	9568-9576	assessed	_	_
44-12	9577-9581	with	_	_
44-13	9582-9585	the	_	_
44-14	9586-9590	Semi	_	_
44-15	9591-9601	Structured	_	_
44-16	9602-9612	Assessment	_	_
44-17	9613-9616	for	_	_
44-18	9617-9620	the	_	_
44-19	9621-9629	Genetics	_	_
44-20	9630-9632	of	_	_
44-21	9633-9643	Alcoholism	_	_
44-22	9644-9647	and	_	_
44-23	9648-9653	based	_	_
44-24	9654-9656	on	_	_
44-25	9657-9666	consensus	_	_
44-26	9667-9675	meetings	_	_
44-27	9676-9680	with	_	_
44-28	9681-9684	the	_	_
44-29	9685-9696	supervising	_	_
44-30	9697-9706	clinician	_	_
44-31	9707-9710	and	_	_
44-32	9711-9718	trained	_	_
44-33	9719-9724	study	_	_
44-34	9725-9734	personnel	_	_
44-35	9734-9735	,	_	_
44-36	9736-9745	including	_	_
44-37	9746-9747	a	_	_
44-38	9748-9761	Masters-level	_	_
44-39	9762-9770	research	_	_
44-40	9771-9780	assistant	_	_
44-41	9781-9784	and	_	_
44-42	9785-9803	postdoctoral-level	_	_
44-43	9804-9816	psychologist	_	_
44-44	9817-9818	(	_	_
44-45	9818-9821	see	_	_
44-46	9822-9835	Supplementary	_	_
44-47	9836-9840	Text	_	_
44-48	9841-9842	1	_	_
44-49	9843-9846	for	_	_
44-50	9847-9856	exclusion	_	_
44-51	9857-9865	criteria	_	_
44-52	9865-9866	)	_	_
44-53	9866-9867	.	_	_

45-1	9868-9883	Methamphetamine	_	_
45-2	9884-9894	dependence	_	_
45-3	9894-9895	,	_	_
45-4	9896-9899	and	_	_
45-5	9900-9903	not	_	_
45-6	9904-9907	DSM	_	_
45-7	9907-9908	-	_	_
45-8	9908-9909	5	_	_
45-9	9910-9919	diagnosis	_	_
45-10	9920-9922	of	_	_
45-11	9923-9938	methamphetamine	_	_
45-12	9939-9942	use	_	_
45-13	9943-9951	disorder	_	_
45-14	9951-9952	,	_	_
45-15	9953-9956	was	_	_
45-16	9957-9965	assessed	_	_
45-17	9966-9973	because	_	_
45-18	9974-9980	DSM-IV	_	_
45-19	9981-9984	was	_	_
45-20	9985-9987	in	_	_
45-21	9988-9994	effect	_	_
45-22	9995-9997	at	_	_
45-23	9998-10001	the	_	_
45-24	10002-10007	start	_	_
45-25	10008-10010	of	_	_
45-26	10011-10014	the	_	_
45-27	10015-10020	study	_	_
45-28	10020-10021	.	_	_

46-1	10022-10034	Participants	_	_
46-2	10035-10039	were	_	_
46-3	10040-10049	contacted	_	_
46-4	10050-10053	one	_	_
46-5	10054-10058	year	_	_
46-6	10059-10064	later	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
46-7	10065-10068	for	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
46-8	10069-10070	a	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
46-9	10071-10076	brief	_	_
46-10	10077-10087	structured	_	_
46-11	10088-10093	phone	_	_
46-12	10094-10103	interview	_	_
46-13	10104-10106	to	_	_
46-14	10107-10113	assess	_	_
46-15	10114-10117	for	_	_
46-16	10118-10121	any	_	_
46-17	10122-10125	use	_	_
46-18	10126-10128	of	_	_
46-19	10129-10144	methamphetamine	_	_
46-20	10144-10145	,	_	_
46-21	10146-10151	level	_	_
46-22	10152-10154	of	_	_
46-23	10155-10158	use	_	_
46-24	10158-10159	,	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	_
46-25	10160-10163	and	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
46-26	10164-10168	time	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	_
46-27	10169-10171	of	_	_
46-28	10172-10179	relapse	_	_
46-29	10179-10180	.	_	_

47-1	10181-10183	At	_	_
47-2	10184-10192	baseline	_	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
47-3	10192-10193	,	_	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
47-4	10194-10196	we	_	_
47-5	10197-10201	also	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
47-6	10202-10210	assessed	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
47-7	10211-10214	for	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
47-8	10215-10218	use	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
47-9	10219-10222	and	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
47-10	10223-10228	abuse	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
47-11	10228-10229	/	_	_
47-12	10229-10239	dependence	_	_
47-13	10240-10248	criteria	_	_
47-14	10249-10252	for	_	_
47-15	10253-10258	other	_	_
47-16	10259-10264	drugs	_	_
47-17	10265-10266	(	_	_
47-18	10266-10269	i.e	_	_
47-19	10269-10270	.	_	_
47-20	10270-10271	,	_	_
47-21	10272-10281	sedatives	_	_
47-22	10281-10282	,	_	_
47-23	10283-10296	hallucinogens	_	_
47-24	10296-10297	,	_	_
47-25	10298-10307	marijuana	_	_
47-26	10307-10308	,	_	_
47-27	10309-10316	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
47-28	10317-10319	or	_	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
47-29	10320-10327	opiates	_	_
47-30	10327-10328	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
47-31	10329-10331	in	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
47-32	10332-10335	the	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
47-33	10336-10340	past	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
47-34	10341-10345	year	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
47-35	10345-10346	,	_	_
47-36	10347-10349	as	_	_
47-37	10350-10354	part	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
47-38	10355-10357	of	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
47-39	10358-10359	a	_	_
47-40	10360-10366	larger	_	_
47-41	10367-10379	longitudinal	_	_
47-42	10380-10385	study	_	_
47-43	10385-10386	,	_	_
47-44	10387-10392	which	_	_
47-45	10393-10397	also	_	_
47-46	10398-10406	followed	_	_
47-47	10407-10418	individuals	_	_
47-48	10419-10423	with	_	_
47-49	10424-10429	other	_	_
47-50	10430-10437	primary	_	_
47-51	10438-10443	drugs	_	_
47-52	10444-10446	of	_	_
47-53	10447-10452	abuse	_	_
47-54	10452-10453	.	_	_

48-1	10454-10457	For	_	_
48-2	10458-10461	all	_	_
48-3	10462-10474	participants	_	_
48-4	10475-10477	in	_	_
48-5	10478-10482	this	_	_
48-6	10483-10488	study	_	_
48-7	10488-10489	,	_	_
48-8	10490-10505	methamphetamine	_	_
48-9	10506-10509	was	_	_
48-10	10510-10519	confirmed	_	_
48-11	10520-10522	as	_	_
48-12	10523-10535	participants	_	_
48-13	10535-10536	'	_	_
48-14	10537-10541	drug	_	_
48-15	10542-10544	of	_	_
48-16	10545-10551	choice	_	_
48-17	10551-10552	.	_	_

49-1	10553-10560	Relapse	_	_
49-2	10561-10564	was	_	_
49-3	10565-10572	defined	_	_
49-4	10573-10575	as	_	_
49-5	10576-10579	use	_	_
49-6	10580-10582	of	_	_
49-7	10583-10598	methamphetamine	_	_
49-8	10599-10601	at	_	_
49-9	10602-10605	any	_	_
49-10	10606-10611	point	_	_
49-11	10612-10618	during	_	_
49-12	10619-10622	the	_	_
49-13	10623-10632	follow-up	_	_
49-14	10633-10639	period	_	_
49-15	10639-10640	,	_	_
49-16	10641-10646	while	_	_
49-17	10647-10651	some	_	_
49-18	10652-10664	participants	_	_
49-19	10665-10668	may	_	_
49-20	10669-10673	have	_	_
49-21	10674-10686	additionally	_	_
49-22	10687-10695	relapsed	_	_
49-23	10696-10698	to	_	_
49-24	10699-10702	any	_	_
49-25	10703-10705	of	_	_
49-26	10706-10711	these	_	_
49-27	10712-10717	other	_	_
49-28	10718-10728	substances	_	_
49-29	10729-10730	(	_	_
49-30	10730-10733	not	_	_
49-31	10734-10742	assessed	_	_
49-32	10743-10745	at	_	_
49-33	10746-10755	follow-up	_	_
49-34	10755-10756	)	_	_
49-35	10756-10757	.	_	_

50-1	10758-10763	Based	_	_
50-2	10764-10766	on	_	_
50-3	10767-10776	interview	_	_
50-4	10777-10786	responses	_	_
50-5	10786-10787	,	_	_
50-6	10788-10799	thirty-nine	_	_
50-7	10800-10825	methamphetamine-dependent	_	_
50-8	10826-10837	individuals	_	_
50-9	10838-10846	remained	_	_
50-10	10847-10856	abstinent	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
50-11	10857-10861	from	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
50-12	10862-10877	methamphetamine	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
50-13	10878-10882	from	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
50-14	10883-10886	the	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
50-15	10887-10891	time	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
50-16	10892-10894	of	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
50-17	10895-10904	treatment	_	_
50-18	10905-10907	to	_	_
50-19	10908-10916	one-year	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
50-20	10917-10926	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
50-21	10926-10927	.	_	_

51-1	10928-10936	Nineteen	_	_
51-2	10937-10948	individuals	_	_
51-3	10949-10957	reported	_	_
51-4	10958-10962	that	_	_
51-5	10963-10967	they	_	_
51-6	10968-10976	relapsed	_	_
51-7	10976-10977	.	_	_

52-1	10978-10982	Four	_	_
52-2	10983-10995	participants	_	_
52-3	10996-11001	could	_	_
52-4	11002-11005	not	_	_
52-5	11006-11008	be	_	_
52-6	11009-11016	tracked	_	_
52-7	11016-11017	.	_	_

53-1	11018-11022	Stop	_	_
53-2	11023-11029	signal	_	_
53-3	11030-11034	task	_	_
53-4	11035-11047	Participants	_	_
53-5	11048-11057	completed	_	_
53-6	11058-11059	a	_	_
53-7	11060-11071	stop-signal	_	_
53-8	11072-11076	task	_	_
53-9	11077-11078	(	_	_
53-10	11078-11079	6	_	_
53-11	11080-11086	blocks	_	_
53-12	11087-11089	of	_	_
53-13	11090-11092	48	_	_
53-14	11093-11099	trials	_	_
53-15	11099-11100	)	_	_
53-16	11101-11106	while	_	_
53-17	11107-11117	undergoing	_	_
53-18	11118-11122	fMRI	_	_
53-19	11122-11123	.	_	_

54-1	11124-11126	On	_	_
54-2	11127-11130	216	_	_
54-3	11131-11133	go	_	_
54-4	11134-11140	trials	_	_
54-5	11141-11142	(	_	_
54-6	11142-11145	75%	_	_
54-7	11146-11148	of	_	_
54-8	11149-11152	all	_	_
54-9	11153-11159	trials	_	_
54-10	11159-11160	)	_	_
54-11	11160-11161	,	_	_
54-12	11162-11166	they	_	_
54-13	11167-11170	had	_	_
54-14	11171-11173	to	_	_
54-15	11174-11179	press	_	_
54-16	11180-11182	as	_	_
54-17	11183-11187	fast	_	_
54-18	11188-11190	as	_	_
54-19	11191-11199	possible	_	_
54-20	11200-11203	the	_	_
54-21	11204-11208	left	_	_
54-22	11209-11215	button	_	_
54-23	11216-11220	when	_	_
54-24	11221-11223	an	_	_
54-25	11224-11225	â€˜	_	_
54-26	11225-11226	X	_	_
54-27	11226-11227	'	_	_
54-28	11228-11236	appeared	_	_
54-29	11237-11239	or	_	_
54-30	11240-11243	the	_	_
54-31	11244-11249	right	_	_
54-32	11250-11256	button	_	_
54-33	11257-11261	when	_	_
54-34	11262-11264	an	_	_
54-35	11265-11266	â€˜	_	_
54-36	11266-11267	O	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
54-37	11267-11268	'	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
54-38	11269-11277	appeared	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
54-39	11277-11278	.	_	_

55-1	11279-11281	On	_	_
55-2	11282-11284	72	_	_
55-3	11285-11289	stop	_	_
55-4	11290-11296	trials	_	_
55-5	11297-11298	(	_	_
55-6	11298-11301	25%	_	_
55-7	11302-11304	of	_	_
55-8	11305-11308	all	_	_
55-9	11309-11315	trials	_	_
55-10	11315-11316	)	_	_
55-11	11316-11317	,	_	_
55-12	11318-11322	they	_	_
55-13	11323-11328	heard	_	_
55-14	11329-11330	a	_	_
55-15	11331-11335	tone	_	_
55-16	11336-11343	shortly	_	_
55-17	11344-11349	after	_	_
55-18	11350-11355	onset	_	_
55-19	11356-11358	of	_	_
55-20	11359-11362	the	_	_
55-21	11363-11365	go	_	_
55-22	11366-11374	stimulus	_	_
55-23	11374-11375	,	_	_
55-24	11376-11381	which	_	_
55-25	11382-11392	instructed	_	_
55-26	11393-11397	them	_	_
55-27	11398-11401	not	_	_
55-28	11402-11404	to	_	_
55-29	11405-11410	press	_	_
55-30	11411-11417	either	_	_
55-31	11418-11424	button	_	_
55-32	11424-11425	.	_	_

56-1	11426-11430	Each	_	_
56-2	11431-11436	trial	_	_
56-3	11437-11443	lasted	_	_
56-4	11444-11450	around	_	_
56-5	11451-11455	1300	_	_
56-6	11455-11456	â€¯	_	_
56-7	11456-11458	ms	_	_
56-8	11458-11459	,	_	_
56-9	11460-11463	and	_	_
56-10	11464-11470	trials	_	_
56-11	11471-11475	were	_	_
56-12	11476-11485	separated	_	_
56-13	11486-11488	by	_	_
56-14	11489-11490	a	_	_
56-15	11491-11494	200	_	_
56-16	11494-11495	-	_	_
56-17	11495-11497	ms	_	_
56-18	11498-11512	inter-stimulus	_	_
56-19	11513-11522	intervals	_	_
56-20	11523-11524	(	_	_
56-21	11524-11529	blank	_	_
56-22	11530-11536	screen	_	_
56-23	11536-11537	)	_	_
56-24	11537-11538	.	_	_

57-1	11539-11550	Individuals	_	_
57-2	11550-11551	'	_	_
57-3	11552-11560	reaction	_	_
57-4	11561-11565	time	_	_
57-5	11566-11567	(	_	_
57-6	11567-11571	time	_	_
57-7	11572-11576	from	_	_
57-8	11577-11585	stimulus	_	_
57-9	11586-11591	onset	_	_
57-10	11592-11594	to	_	_
57-11	11595-11601	button	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
57-12	11602-11607	press	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
57-13	11607-11608	)	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
57-14	11609-11617	provided	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
57-15	11618-11619	a	_	_
57-16	11620-11627	natural	_	_
57-17	11628-11634	jitter	_	_
57-18	11634-11635	.	_	_

58-1	11636-11639	The	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-2	11640-11648	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-3	11649-11651	of	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-4	11652-11657	trial	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-5	11658-11663	types	_	_
58-6	11664-11673	presented	_	_
58-7	11674-11677	was	_	_
58-8	11678-11695	pseudo-randomized	_	_
58-9	11695-11696	.	_	_

59-1	11697-11704	Finally	_	_
59-2	11704-11705	,	_	_
59-3	11706-11711	prior	_	_
59-4	11712-11714	to	_	_
59-5	11715-11723	scanning	_	_
59-6	11723-11724	,	_	_
59-7	11725-11737	participants	_	_
59-8	11738-11747	completed	_	_
59-9	11748-11751	the	_	_
59-10	11752-11755	SST	_	_
59-11	11756-11763	outside	_	_
59-12	11764-11767	the	_	_
59-13	11768-11775	scanner	_	_
59-14	11776-11778	to	_	_
59-15	11779-11788	determine	_	_
59-16	11789-11794	their	_	_
59-17	11795-11799	mean	_	_
59-18	11800-11801	â€˜	_	_
59-19	11801-11803	Go	_	_
59-20	11803-11804	â€™	_	_
59-21	11805-11813	reaction	_	_
59-22	11814-11818	time	_	_
59-23	11819-11820	(	_	_
59-24	11820-11823	MRT	_	_
59-25	11823-11824	)	_	_
59-26	11824-11825	.	_	_

60-1	11826-11830	This	_	_
60-2	11831-11838	measure	_	_
60-3	11839-11842	was	_	_
60-4	11843-11847	then	_	_
60-5	11848-11852	used	_	_
60-6	11853-11855	to	_	_
60-7	11856-11865	determine	_	_
60-8	11866-11869	the	_	_
60-9	11870-11874	stop	_	_
60-10	11875-11881	signal	_	_
60-11	11882-11887	delay	_	_
60-12	11888-11889	(	_	_
60-13	11889-11892	SSD	_	_
60-14	11892-11893	)	_	_
60-15	11894-11897	for	_	_
60-16	11898-11901	six	_	_
60-17	11902-11911	different	_	_
60-18	11912-11917	types	_	_
60-19	11918-11922	stop	_	_
60-20	11923-11928	trial	_	_
60-21	11929-11931	of	_	_
60-22	11932-11942	increasing	_	_
60-23	11943-11953	difficulty	_	_
60-24	11953-11954	,	_	_
60-25	11955-11964	providing	_	_
60-26	11965-11966	a	_	_
60-27	11967-11984	subject-dependent	_	_
60-28	11985-11993	jittered	_	_
60-29	11994-12003	reference	_	_
60-30	12004-12012	function	_	_
60-31	12012-12013	.	_	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging

61-1	12014-12026	Specifically	_	_
61-2	12026-12027	,	_	_
61-3	12028-12032	stop	_	_
61-4	12033-12040	signals	_	_
61-5	12041-12045	were	_	_
61-6	12046-12055	delivered	_	_
61-7	12056-12058	in	_	_
61-8	12059-12064	equal	_	_
61-9	12065-12072	amounts	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
61-10	12073-12075	at	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	_
61-11	12076-12079	MRT	_	_
61-12	12079-12080	-	_	_
61-13	12080-12081	0	_	_
61-14	12081-12082	â€¯	_	_
61-15	12082-12084	ms	_	_
61-16	12084-12085	,	_	_
61-17	12086-12089	MRT	_	_
61-18	12089-12090	-	_	_
61-19	12090-12093	100	_	_
61-20	12093-12094	â€¯	_	_
61-21	12094-12096	ms	_	_
61-22	12096-12097	,	_	_
61-23	12098-12101	MRT	_	_
61-24	12101-12102	-	_	_
61-25	12102-12105	200	_	_
61-26	12105-12106	â€¯	_	_
61-27	12106-12108	ms	_	_
61-28	12108-12109	,	_	_
61-29	12110-12113	MRT	_	_
61-30	12113-12114	-	_	_
61-31	12114-12117	300	_	_
61-32	12117-12118	â€¯	_	_
61-33	12118-12120	ms	_	_
61-34	12120-12121	,	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
61-35	12122-12125	MRT	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
61-36	12125-12126	-	_	_
61-37	12126-12129	400	_	_
61-38	12129-12130	â€¯	_	_
61-39	12130-12132	ms	_	_
61-40	12132-12133	,	_	_
61-41	12134-12137	and	_	_
61-42	12138-12141	MRT	_	_
61-43	12141-12142	-	_	_
61-44	12142-12145	500	_	_
61-45	12145-12146	â€¯	_	_
61-46	12146-12148	ms	_	_
61-47	12149-12158	providing	_	_
61-48	12159-12161	an	_	_
61-49	12162-12174	individually	_	_
61-50	12175-12185	customized	_	_
61-51	12186-12191	range	_	_
61-52	12192-12194	of	_	_
61-53	12195-12205	difficulty	_	_
61-54	12205-12206	;	_	_
61-55	12207-12210	see	_	_
61-56	12211-12224	Supplementary	_	_
61-57	12225-12229	Text	_	_
61-58	12230-12231	2	_	_
61-59	12232-12235	for	_	_
61-60	12236-12240	task	_	_
61-61	12241-12253	instructions	_	_
61-62	12253-12254	)	_	_
61-63	12254-12255	.	_	_

62-1	12256-12264	Bayesian	_	_
62-2	12265-12270	model	_	_
62-3	12271-12273	of	_	_
62-4	12274-12277	the	_	_
62-5	12278-12288	inhibitory	_	_
62-6	12289-12297	response	_	_
62-7	12298-12309	expectation	_	_
62-8	12310-12312	To	_	_
62-9	12313-12318	model	_	_
62-10	12319-12327	behavior	_	_
62-11	12327-12328	,	_	_
62-12	12329-12331	we	_	_
62-13	12332-12336	used	_	_
62-14	12337-12338	a	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
62-15	12339-12352	Bayes-optimal	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
62-16	12353-12360	Dynamic	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
62-17	12361-12367	Belief	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
62-18	12368-12373	Model	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
62-19	12373-12374	,	_	_
62-20	12375-12380	which	_	_
62-21	12381-12384	has	_	_
62-22	12385-12389	been	_	_
62-23	12390-12398	robustly	_	_
62-24	12399-12410	established	_	_
62-25	12411-12413	to	_	_
62-26	12414-12421	capture	_	_
62-27	12422-12432	behavioral	_	_
62-28	12433-12444	adjustments	_	_
62-29	12445-12447	in	_	_
62-30	12448-12451	the	_	_
62-31	12452-12455	SST	_	_
62-32	12456-12458	in	_	_
62-33	12459-12463	both	_	_
62-34	12464-12471	healthy	_	_
62-35	12472-12483	individuals	_	_
62-36	12484-12487	and	_	_
62-37	12488-12497	substance	_	_
62-38	12498-12503	users	_	_
62-39	12503-12504	.	_	_

63-1	12505-12508	The	_	_
63-2	12509-12514	model	_	_
63-3	12515-12522	assumes	_	_
63-4	12523-12527	that	_	_
63-5	12528-12531	one	_	_
63-6	12532-12533	1	_	_
63-7	12533-12534	)	_	_
63-8	12535-12542	updates	_	_
63-9	12543-12546	the	_	_
63-10	12547-12552	prior	_	_
63-11	12553-12564	probability	_	_
63-12	12565-12567	of	_	_
63-13	12568-12580	encountering	_	_
63-14	12581-12585	stop	_	_
63-15	12586-12592	trials	_	_
63-16	12592-12593	,	_	_
63-17	12594-12595	P	_	_
63-18	12595-12596	(	_	_
63-19	12596-12600	stop	_	_
63-20	12600-12601	)	_	_
63-21	12601-12602	,	_	_
63-22	12603-12605	on	_	_
63-23	12606-12607	a	_	_
63-24	12608-12622	trial-by-trial	_	_
63-25	12623-12628	basis	_	_
63-26	12629-12634	based	_	_
63-27	12635-12637	on	_	_
63-28	12638-12643	trial	_	_
63-29	12644-12651	history	_	_
63-30	12651-12652	,	_	_
63-31	12653-12656	and	_	_
63-32	12657-12658	2	_	_
63-33	12658-12659	)	_	_
63-34	12660-12667	adjusts	_	_
63-35	12668-12676	behavior	_	_
63-36	12677-12679	as	_	_
63-37	12680-12681	a	_	_
63-38	12682-12690	function	_	_
63-39	12691-12693	of	_	_
63-40	12694-12695	P	_	_
63-41	12695-12696	(	_	_
63-42	12696-12700	stop	_	_
63-43	12700-12701	)	_	_
63-44	12702-12706	with	_	_
63-45	12707-12713	higher	_	_
63-46	12714-12723	predicted	_	_
63-47	12724-12725	P	_	_
63-48	12725-12726	(	_	_
63-49	12726-12730	stop	_	_
63-50	12730-12731	)	_	_
63-51	12732-12741	prompting	_	_
63-52	12742-12748	slower	_	_
63-53	12749-12751	Go	_	_
63-54	12752-12754	RT	_	_
63-55	12755-12758	and	_	_
63-56	12759-12765	higher	_	_
63-57	12766-12776	likelihood	_	_
63-58	12777-12779	of	_	_
63-59	12780-12789	correctly	_	_
63-60	12790-12798	stopping	_	_
63-61	12799-12801	on	_	_
63-62	12802-12803	a	_	_
63-63	12804-12808	stop	_	_
63-64	12809-12814	trial	_	_
63-65	12814-12815	.	_	_

64-1	12816-12830	Mathematically	_	_
64-2	12830-12831	,	_	_
64-3	12832-12834	on	_	_
64-4	12835-12839	each	_	_
64-5	12840-12845	trial	_	_
64-6	12846-12847	k	_	_
64-7	12847-12848	,	_	_
64-8	12849-12851	Pk	_	_
64-9	12851-12852	(	_	_
64-10	12852-12856	stop	_	_
64-11	12856-12857	)	_	_
64-12	12858-12860	is	_	_
64-13	12861-12864	the	_	_
64-14	12865-12869	mean	_	_
64-15	12870-12872	of	_	_
64-16	12873-12876	the	_	_
64-17	12877-12887	predictive	_	_
64-18	12888-12900	distribution	_	_
64-19	12901-12902	p	_	_
64-20	12902-12903	(	_	_
64-21	12903-12905	rk	_	_
64-22	12905-12906	|	_	_
64-23	12906-12908	sk	_	_
64-24	12908-12909	-	_	_
64-25	12909-12910	1	_	_
64-26	12910-12911	)	_	_
64-27	12911-12912	,	_	_
64-28	12913-12918	which	_	_
64-29	12919-12921	is	_	_
64-30	12922-12923	a	_	_
64-31	12924-12931	mixture	_	_
64-32	12932-12934	of	_	_
64-33	12935-12938	the	_	_
64-34	12939-12947	previous	_	_
64-35	12948-12957	posterior	_	_
64-36	12958-12970	distribution	_	_
64-37	12971-12974	and	_	_
64-38	12975-12976	a	_	_
64-39	12977-12982	fixed	_	_
64-40	12983-12988	prior	_	_
64-41	12989-13001	distribution	_	_
64-42	13001-13002	,	_	_
64-43	13003-13007	with	_	_
64-44	13008-13009	Î±	_	_
64-45	13010-13013	and	_	_
64-46	13014-13015	1	_	_
64-47	13015-13016	â€¯	_	_
64-48	13016-13017	âˆ’	_	_
64-49	13017-13018	â€¯	_	_
64-50	13018-13019	Î±	_	_
64-51	13020-13026	acting	_	_
64-52	13027-13029	as	_	_
64-53	13030-13033	the	_	_
64-54	13034-13040	mixing	_	_
64-55	13041-13053	coefficients	_	_
64-56	13053-13054	,	_	_
64-57	13055-13067	respectively	_	_
64-58	13067-13068	,	_	_
64-59	13069-13072	and	_	_
64-60	13073-13078	where	_	_
64-61	13079-13081	Sk	_	_
64-62	13081-13082	â€¯	_	_
64-63	13082-13083	=	_	_
64-64	13083-13084	â€¯	_	_
64-65	13084-13085	(	_	_
64-66	13085-13087	s1	_	_
64-67	13087-13088	,	_	_
64-68	13089-13090	â€¦	_	_
64-69	13090-13091	,	_	_
64-70	13091-13093	sk	_	_
64-71	13093-13094	)	_	_
64-72	13095-13097	is	_	_
64-73	13098-13099	1	_	_
64-74	13100-13102	on	_	_
64-75	13103-13107	stop	_	_
64-76	13108-13114	trials	_	_
64-77	13115-13118	and	_	_
64-78	13119-13120	0	_	_
64-79	13121-13123	on	_	_
64-80	13124-13126	go	_	_
64-81	13127-13133	trials	_	_
64-82	13133-13134	:	_	_
64-83	13135-13139	with	_	_
64-84	13140-13143	the	_	_
64-85	13144-13153	posterior	_	_
64-86	13154-13166	distribution	_	_
64-87	13167-13172	being	_	_
64-88	13173-13180	updated	_	_
64-89	13181-13190	according	_	_
64-90	13191-13193	to	_	_
64-91	13194-13199	Bayes	_	_
64-92	13199-13200	'	_	_
64-93	13201-13205	Rule	_	_
64-94	13205-13206	:	_	_
64-95	13207-13208	A	_	_
64-96	13208-13209	.	_	_

65-1	13210-13211	P	_	_
65-2	13211-13212	(	_	_
65-3	13212-13216	stop	_	_
65-4	13216-13217	)	_	_
65-5	13218-13220	as	_	_
65-6	13221-13222	a	_	_
65-7	13223-13231	function	_	_
65-8	13232-13234	of	_	_
65-9	13235-13240	trial	_	_
65-10	13241-13249	sequence	_	_
65-11	13249-13250	.	_	_

66-1	13251-13254	Top	_	_
66-2	13254-13255	:	_	_
66-3	13256-13259	for	_	_
66-4	13260-13263	the	_	_
66-5	13264-13272	sequence	_	_
66-6	13273-13275	of	_	_
66-7	13276-13278	go	_	_
66-8	13279-13280	(	_	_
66-9	13280-13285	green	_	_
66-10	13286-13290	dots	_	_
66-11	13290-13291	,	_	_
66-12	13292-13299	outcome	_	_
66-13	13299-13300	â€¯	_	_
66-14	13300-13301	=	_	_
66-15	13301-13302	â€¯	_	_
66-16	13302-13303	0	_	_
66-17	13303-13304	)	_	_
66-18	13305-13308	and	_	_
66-19	13309-13313	stop	_	_
66-20	13314-13315	(	_	_
66-21	13315-13319	blue	_	_
66-22	13320-13324	dots	_	_
66-23	13324-13325	,	_	_
66-24	13326-13333	outcome	_	_
66-25	13333-13334	â€¯	_	_
66-26	13334-13335	=	_	_
66-27	13335-13336	â€¯	_	_
66-28	13336-13337	1	_	_
66-29	13337-13338	)	_	_
66-30	13339-13345	trials	_	_
66-31	13345-13346	,	_	_
66-32	13347-13355	Bayesian	_	_
66-33	13356-13361	prior	_	_
66-34	13362-13368	belief	_	_
66-35	13369-13374	about	_	_
66-36	13375-13387	encountering	_	_
66-37	13388-13389	a	_	_
66-38	13390-13394	stop	_	_
66-39	13395-13400	trial	_	_
66-40	13401-13402	(	_	_
66-41	13402-13403	P	_	_
66-42	13403-13404	(	_	_
66-43	13404-13408	stop	_	_
66-44	13408-13409	)	_	_
66-45	13409-13410	,	_	_
66-46	13411-13414	red	_	_
66-47	13415-13419	line	_	_
66-48	13419-13420	)	_	_
66-49	13420-13421	,	_	_
66-50	13422-13424	as	_	_
66-51	13425-13434	predicted	_	_
66-52	13435-13437	by	_	_
66-53	13438-13441	the	_	_
66-54	13442-13449	Dynamic	_	_
66-55	13450-13456	Belief	_	_
66-56	13457-13462	Model	_	_
66-57	13462-13463	.	_	_

67-1	13464-13465	P	_	_
67-2	13465-13466	(	_	_
67-3	13466-13470	stop	_	_
67-4	13470-13471	)	_	_
67-5	13472-13481	increases	_	_
67-6	13482-13487	after	_	_
67-7	13488-13492	each	_	_
67-8	13493-13497	stop	_	_
67-9	13498-13503	trial	_	_
67-10	13503-13504	,	_	_
67-11	13505-13508	and	_	_
67-12	13509-13518	decreases	_	_
67-13	13519-13524	after	_	_
67-14	13525-13529	each	_	_
67-15	13530-13532	go	_	_
67-16	13533-13538	trial	_	_
67-17	13538-13539	.	_	_

68-1	13540-13546	Bottom	_	_
68-2	13546-13547	:	_	_
68-3	13548-13551	The	_	_
68-4	13552-13565	corresponding	_	_
68-5	13566-13572	signed	_	_
68-6	13573-13583	prediction	_	_
68-7	13584-13589	error	_	_
68-8	13590-13591	(	_	_
68-9	13591-13594	SPE	_	_
68-10	13594-13595	,	_	_
68-11	13596-13599	red	_	_
68-12	13600-13604	line	_	_
68-13	13604-13605	,	_	_
68-14	13606-13611	solid	_	_
68-15	13611-13612	)	_	_
68-16	13612-13613	,	_	_
68-17	13614-13617	SPE	_	_
68-18	13617-13618	â€¯	_	_
68-19	13618-13619	=	_	_
68-20	13619-13620	â€¯	_	_
68-21	13620-13628	stimulus	_	_
68-22	13629-13636	outcome	_	_
68-23	13637-13638	âˆ’	_	_
68-24	13639-13640	P	_	_
68-25	13640-13641	(	_	_
68-26	13641-13645	stop	_	_
68-27	13645-13646	)	_	_
68-28	13646-13647	,	_	_
68-29	13648-13651	and	_	_
68-30	13652-13660	unsigned	_	_
68-31	13661-13671	prediction	_	_
68-32	13672-13677	error	_	_
68-33	13678-13679	(	_	_
68-34	13679-13682	UPE	_	_
68-35	13682-13683	,	_	_
68-36	13684-13688	blue	_	_
68-37	13688-13689	,	_	_
68-38	13690-13696	dashed	_	_
68-39	13696-13697	)	_	_
68-40	13697-13698	,	_	_
68-41	13699-13702	SPE	_	_
68-42	13702-13703	â€¯	_	_
68-43	13703-13704	=	_	_
68-44	13704-13705	â€¯	_	_
68-45	13705-13706	|	_	_
68-46	13706-13714	stimulus	_	_
68-47	13715-13722	outcome	_	_
68-48	13723-13724	âˆ’	_	_
68-49	13725-13726	P	_	_
68-50	13726-13727	(	_	_
68-51	13727-13731	stop	_	_
68-52	13731-13732	)	_	_
68-53	13732-13733	|	_	_
68-54	13733-13734	.	_	_

69-1	13735-13736	B	_	_
69-2	13736-13737	.	_	_

70-1	13738-13743	Model	_	_
70-2	13744-13747	fit	_	_
70-3	13748-13751	for	_	_
70-4	13752-13756	both	_	_
70-5	13757-13772	methamphetamine	_	_
70-6	13773-13782	dependent	_	_
70-7	13783-13794	individuals	_	_
70-8	13795-13798	who	_	_
70-9	13799-13809	maintained	_	_
70-10	13810-13820	abstinence	_	_
70-11	13821-13825	over	_	_
70-12	13826-13827	a	_	_
70-13	13828-13829	1	_	_
70-14	13829-13830	â€¯	_	_
70-15	13830-13834	year	_	_
70-16	13835-13836	(	_	_
70-17	13836-13841	black	_	_
70-18	13841-13842	;	_	_
70-19	13843-13844	n	_	_
70-20	13844-13845	â€¯	_	_
70-21	13845-13846	=	_	_
70-22	13846-13847	â€¯	_	_
70-23	13847-13849	39	_	_
70-24	13849-13850	)	_	_
70-25	13851-13854	and	_	_
70-26	13855-13860	those	_	_
70-27	13861-13864	who	_	_
70-28	13865-13873	relapsed	_	_
70-29	13874-13880	within	_	_
70-30	13881-13882	1	_	_
70-31	13882-13883	â€¯	_	_
70-32	13883-13887	year	_	_
70-33	13888-13890	of	_	_
70-34	13891-13900	treatment	_	_
70-35	13901-13902	(	_	_
70-36	13902-13905	red	_	_
70-37	13905-13906	;	_	_
70-38	13907-13908	n	_	_
70-39	13908-13909	â€¯	_	_
70-40	13909-13910	=	_	_
70-41	13910-13911	â€¯	_	_
70-42	13911-13913	19	_	_
70-43	13913-13914	)	_	_
70-44	13914-13915	;	_	_
70-45	13916-13920	data	_	_
70-46	13921-13930	collapsed	_	_
70-47	13931-13937	across	_	_
70-48	13938-13941	all	_	_
70-49	13942-13950	subjects	_	_
70-50	13951-13954	for	_	_
70-51	13955-13963	relapsed	_	_
70-52	13964-13967	and	_	_
70-53	13968-13977	abstinent	_	_
70-54	13978-13984	groups	_	_
70-55	13985-13995	separately	_	_
70-56	13995-13996	,	_	_
70-57	13997-14002	where	_	_
70-58	14003-14005	Go	_	_
70-59	14006-14012	trials	_	_
70-60	14013-14017	were	_	_
70-61	14018-14024	binned	_	_
70-62	14025-14027	by	_	_
70-63	14028-14029	P	_	_
70-64	14029-14030	(	_	_
70-65	14030-14034	stop	_	_
70-66	14034-14035	)	_	_
70-67	14036-14039	and	_	_
70-68	14040-14047	average	_	_
70-69	14048-14050	RT	_	_
70-70	14051-14061	calculated	_	_
70-71	14062-14065	for	_	_
70-72	14066-14070	each	_	_
70-73	14071-14074	bin	_	_
70-74	14075-14085	separately	_	_
70-75	14085-14086	;	_	_
70-76	14087-14089	as	_	_
70-77	14090-14099	predicted	_	_
70-78	14100-14102	by	_	_
70-79	14103-14106	our	_	_
70-80	14107-14112	Bayes	_	_
70-81	14113-14120	optimal	_	_
70-82	14121-14136	decision-making	_	_
70-83	14137-14142	model	_	_
70-84	14142-14143	,	_	_
70-85	14144-14145	a	_	_
70-86	14146-14157	significant	_	_
70-87	14158-14166	positive	_	_
70-88	14167-14179	relationship	_	_
70-89	14180-14183	was	_	_
70-90	14184-14192	observed	_	_
70-91	14193-14200	between	_	_
70-92	14201-14212	individuals	_	_
70-93	14212-14213	'	_	_
70-94	14214-14216	Go	_	_
70-95	14217-14225	reaction	_	_
70-96	14226-14231	times	_	_
70-97	14232-14233	(	_	_
70-98	14233-14235	RT	_	_
70-99	14235-14236	)	_	_
70-100	14237-14240	and	_	_
70-101	14241-14251	trial-wise	_	_
70-102	14252-14253	P	_	_
70-103	14253-14254	(	_	_
70-104	14254-14258	stop	_	_
70-105	14258-14259	)	_	_
70-106	14260-14265	model	_	_
70-107	14266-14275	estimates	_	_
70-108	14276-14278	in	_	_
70-109	14279-14283	each	_	_
70-110	14284-14289	group	_	_
70-111	14289-14290	;	_	_
70-112	14291-14296	black	_	_
70-113	14297-14300	and	_	_
70-114	14301-14304	red	_	_
70-115	14305-14310	lines	_	_
70-116	14311-14320	represent	_	_
70-117	14321-14325	best	_	_
70-118	14326-14332	linear	_	_
70-119	14333-14343	regression	_	_
70-120	14344-14347	fit	_	_
70-121	14348-14350	to	_	_
70-122	14351-14355	mean	_	_
70-123	14356-14358	go	_	_
70-124	14359-14367	reaction	_	_
70-125	14368-14372	time	_	_
70-126	14373-14376	for	_	_
70-127	14377-14381	each	_	_
70-128	14382-14387	group	_	_
70-129	14387-14388	.	_	_

71-1	14389-14394	Error	_	_
71-2	14395-14399	bars	_	_
71-3	14399-14400	â€¯	_	_
71-4	14400-14401	=	_	_
71-5	14401-14402	â€¯	_	_
71-6	14402-14405	SEM	_	_
71-7	14405-14406	.	_	_

72-1	14407-14410	Fig	_	_
72-2	14410-14411	.	_	_
72-3	14412-14413	1	_	_
72-4	14414-14416	In	_	_
72-5	14417-14421	this	_	_
72-6	14422-14427	study	_	_
72-7	14427-14428	,	_	_
72-8	14429-14434	model	_	_
72-9	14435-14445	parameters	_	_
72-10	14446-14449	for	_	_
72-11	14450-14453	the	_	_
72-12	14454-14458	beta	_	_
72-13	14459-14471	distribution	_	_
72-14	14472-14474	p0	_	_
72-15	14474-14475	(	_	_
72-16	14475-14476	r	_	_
72-17	14476-14477	)	_	_
72-18	14478-14481	and	_	_
72-19	14482-14483	Î±	_	_
72-20	14484-14488	were	_	_
72-21	14489-14493	kept	_	_
72-22	14494-14502	constant	_	_
72-23	14503-14509	across	_	_
72-24	14510-14513	all	_	_
72-25	14514-14526	participants	_	_
72-26	14526-14527	,	_	_
72-27	14528-14533	based	_	_
72-28	14534-14536	on	_	_
72-29	14537-14542	prior	_	_
72-30	14543-14554	simulations	_	_
72-31	14555-14559	that	_	_
72-32	14560-14566	sought	_	_
72-33	14567-14569	to	_	_
72-34	14570-14578	optimize	_	_
72-35	14579-14589	behavioral	_	_
72-36	14590-14593	fit	_	_
72-37	14594-14596	at	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
72-38	14597-14600	the	_	_
72-39	14601-14606	group	_	_
72-40	14607-14612	level	_	_
72-41	14612-14613	,	_	_
72-42	14614-14617	i.e	_	_
72-43	14617-14618	.	_	_
72-44	14618-14619	,	_	_
72-45	14620-14630	maximizing	_	_
72-46	14631-14634	the	_	_
72-47	14635-14650	goodness-of-fit	_	_
72-48	14651-14653	of	_	_
72-49	14654-14657	the	_	_
72-50	14658-14664	linear	_	_
72-51	14665-14675	regression	_	_
72-52	14676-14678	of	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
72-53	14679-14680	P	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
72-54	14680-14681	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
72-55	14681-14685	Stop	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
72-56	14685-14686	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
72-57	14687-14689	on	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
72-58	14690-14692	RT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
72-59	14693-14699	across	_	_
72-60	14700-14703	all	_	_
72-61	14704-14716	participants	_	_
72-62	14717-14718	(	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
72-63	14718-14721	see	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
72-64	14722-14735	Supplementary	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
72-65	14736-14740	Text	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
72-66	14741-14742	3	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
72-67	14742-14743	)	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
72-68	14743-14744	.	_	_

73-1	14745-14746	A	_	_
73-2	14747-14752	fixed	_	_
73-3	14753-14760	setting	_	_
73-4	14761-14763	of	_	_
73-5	14764-14766	p0	_	_
73-6	14766-14767	â€¯	_	_
73-7	14767-14768	=	_	_
73-8	14768-14769	â€¯	_	_
73-9	14769-14773	Beta	_	_
73-10	14773-14774	(	_	_
73-11	14774-14775	a	_	_
73-12	14775-14776	â€¯	_	_
73-13	14776-14777	=	_	_
73-14	14777-14778	â€¯	_	_
73-15	14778-14781	2.5	_	_
73-16	14781-14782	,	_	_
73-17	14782-14783	b	_	_
73-18	14783-14784	â€¯	_	_
73-19	14784-14785	=	_	_
73-20	14785-14786	â€¯	_	_
73-21	14786-14789	7.5	_	_
73-22	14789-14790	;	_	_
73-23	14791-14792	s	_	_
73-24	14792-14793	â€¯	_	_
73-25	14793-14794	=	_	_
73-26	14794-14795	â€¯	_	_
73-27	14795-14796	a	_	_
73-28	14796-14797	â€¯	_	_
73-29	14797-14798	+	_	_
73-30	14798-14799	â€¯	_	_
73-31	14799-14800	b	_	_
73-32	14800-14801	â€¯	_	_
73-33	14801-14802	=	_	_
73-34	14802-14803	â€¯	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
73-35	14803-14805	10	_	_
73-36	14805-14806	;	_	_
73-37	14807-14811	mean	_	_
73-38	14811-14812	â€¯	_	_
73-39	14812-14813	=	_	_
73-40	14813-14814	â€¯	_	_
73-41	14814-14818	0.25	_	_
73-42	14818-14819	)	_	_
73-43	14820-14823	was	_	_
73-44	14824-14828	used	_	_
73-45	14828-14829	,	_	_
73-46	14830-14833	and	_	_
73-47	14834-14839	alpha	_	_
73-48	14840-14843	was	_	_
73-49	14844-14847	fit	_	_
73-50	14848-14850	to	_	_
73-51	14851-14863	participants	_	_
73-52	14863-14864	'	_	_
73-53	14865-14869	data	_	_
73-54	14870-14871	(	_	_
73-55	14871-14876	range	_	_
73-56	14877-14883	tested	_	_
73-57	14883-14884	:	_	_
73-58	14885-14889	0.25	_	_
73-59	14889-14890	â€“	_	_
73-60	14890-14893	1.0	_	_
73-61	14893-14894	;	_	_
73-62	14895-14896	Î±	_	_
73-63	14896-14897	â€¯	_	_
73-64	14897-14898	=	_	_
73-65	14898-14899	â€¯	_	_
73-66	14899-14902	0.5	_	_
73-67	14903-14912	maximized	_	_
73-68	14913-14920	overall	_	_
73-69	14921-14924	fit	_	_
73-70	14925-14931	across	_	_
73-71	14932-14935	all	_	_
73-72	14936-14948	participants	_	_
73-73	14948-14949	;	_	_
73-74	14950-14953	see	_	_
73-75	14954-14957	Fig	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
73-76	14957-14958	.	_	_
73-77	14959-14961	1A	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
73-78	14962-14965	for	_	_
73-79	14966-14967	P	_	_
73-80	14967-14968	(	_	_
73-81	14968-14972	stop	_	_
73-82	14972-14973	)	_	_
73-83	14974-14982	sequence	_	_
73-84	14982-14983	)	_	_
73-85	14983-14984	.	_	_

74-1	14985-14990	Image	_	_
74-2	14991-15002	acquisition	_	_
74-3	15003-15006	and	_	_
74-4	15007-15020	preprocessing	_	_
74-5	15021-15026	Using	_	_
74-6	15027-15028	a	_	_
74-7	15029-15033	fast	_	_
74-8	15034-15047	event-related	_	_
74-9	15048-15052	fMRI	_	_
74-10	15053-15059	design	_	_
74-11	15059-15060	,	_	_
74-12	15061-15064	six	_	_
74-13	15065-15067	T2	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
74-14	15067-15068	*	_	_
74-15	15068-15069	-	_	_
74-16	15069-15077	weighted	_	_
74-17	15078-15081	EPI	_	_
74-18	15082-15092	functional	_	_
74-19	15093-15097	runs	_	_
74-20	15098-15102	were	_	_
74-21	15103-15112	collected	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
74-22	15113-15116	for	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
74-23	15117-15121	each	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
74-24	15122-15133	participant	_	_
74-25	15133-15134	,	_	_
74-26	15135-15140	along	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
74-27	15141-15145	with	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
74-28	15146-15149	one	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
74-29	15150-15152	T1	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
74-30	15152-15153	-	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
74-31	15153-15161	weighted	_	_
74-32	15162-15172	anatomical	_	_
74-33	15173-15178	image	_	_
74-34	15178-15179	.	_	_

75-1	15180-15184	Each	_	_
75-2	15185-15193	scanning	_	_
75-3	15194-15201	session	_	_
75-4	15202-15205	was	_	_
75-5	15206-15215	conducted	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
75-6	15216-15218	on	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
75-7	15219-15220	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
75-8	15221-15222	3	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
75-9	15222-15223	â€¯	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
75-10	15223-15224	T	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
75-11	15225-15232	General	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
75-12	15233-15241	Electric	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
75-13	15242-15249	scanner	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
75-14	15250-15254	with	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
75-15	15255-15258	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
75-16	15259-15268	following	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
75-17	15269-15279	parameters	_	_
75-18	15279-15280	:	_	_
75-19	15281-15283	T2	_	_
75-20	15283-15284	*	_	_
75-21	15284-15285	-	_	_
75-22	15285-15293	weighted	_	_
75-23	15294-15297	EPI	_	_
75-24	15297-15298	,	_	_
75-25	15299-15309	repetition	_	_
75-26	15310-15314	time	_	_
75-27	15314-15315	â€¯	_	_
75-28	15315-15316	=	_	_
75-29	15316-15317	â€¯	_	_
75-30	15317-15321	2000	_	_
75-31	15321-15322	â€¯	_	_
75-32	15322-15324	ms	_	_
75-33	15324-15325	,	_	_
75-34	15326-15330	echo	_	_
75-35	15331-15335	time	_	_
75-36	15335-15336	â€¯	_	_
75-37	15336-15337	=	_	_
75-38	15337-15338	â€¯	_	_
75-39	15338-15340	40	_	_
75-40	15340-15341	â€¯	_	_
75-41	15341-15343	ms	_	_
75-42	15343-15344	,	_	_
75-43	15345-15347	64	_	_
75-44	15347-15348	â€¯	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
75-45	15348-15349	Ã—	_	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
75-46	15349-15350	â€¯	_	_
75-47	15350-15352	64	_	_
75-48	15353-15359	matrix	_	_
75-49	15359-15360	,	_	_
75-50	15361-15363	30	_	_
75-51	15364-15365	4	_	_
75-52	15365-15366	-	_	_
75-53	15366-15368	mm	_	_
75-54	15369-15374	axial	_	_
75-55	15375-15381	slices	_	_
75-56	15381-15382	,	_	_
75-57	15383-15386	FOV	_	_
75-58	15386-15387	â€¯	_	_
75-59	15387-15388	=	_	_
75-60	15388-15389	â€¯	_	_
75-61	15389-15392	220	_	_
75-62	15392-15393	â€¯	_	_
75-63	15393-15394	Ã—	_	_
75-64	15394-15395	â€¯	_	_
75-65	15395-15398	220	_	_
75-66	15398-15399	â€¯	_	_
75-67	15399-15401	mm	_	_
75-68	15401-15402	,	_	_
75-69	15403-15411	in-plane	_	_
75-70	15412-15417	voxel	_	_
75-71	15418-15422	size	_	_
75-72	15422-15423	â€¯	_	_
75-73	15423-15424	=	_	_
75-74	15424-15425	â€¯	_	_
75-75	15425-15430	3.437	_	_
75-76	15430-15431	,	_	_
75-77	15432-15435	and	_	_
75-78	15436-15440	flip	_	_
75-79	15441-15446	angle	_	_
75-80	15446-15447	â€¯	_	_
75-81	15447-15448	=	_	_
75-82	15448-15449	â€¯	_	_
75-83	15449-15452	90o	_	_
75-84	15452-15453	.	_	_

76-1	15454-15458	Each	_	_
76-2	15459-15462	run	_	_
76-3	15463-15471	included	_	_
76-4	15472-15475	256	_	_
76-5	15476-15487	repetitions	_	_
76-6	15488-15491	for	_	_
76-7	15492-15493	a	_	_
76-8	15494-15500	length	_	_
76-9	15501-15503	of	_	_
76-10	15504-15505	8	_	_
76-11	15505-15506	â€¯	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
76-12	15506-15509	min	_	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
76-13	15510-15513	and	_	_
76-14	15514-15516	32	_	_
76-15	15516-15517	â€¯	_	_
76-16	15517-15518	s	_	_
76-17	15518-15519	.	_	_

77-1	15520-15530	Functional	_	_
77-2	15531-15537	volume	_	_
77-3	15538-15550	acquisitions	_	_
77-4	15551-15555	were	_	_
77-5	15556-15567	time-locked	_	_
77-6	15568-15570	to	_	_
77-7	15571-15575	task	_	_
77-8	15576-15581	onset	_	_
77-9	15581-15582	.	_	_

78-1	15583-15589	During	_	_
78-2	15590-15593	the	_	_
78-3	15594-15598	same	_	_
78-4	15599-15611	experimental	_	_
78-5	15612-15619	session	_	_
78-6	15619-15620	,	_	_
78-7	15621-15623	we	_	_
78-8	15624-15633	collected	_	_
78-9	15634-15635	a	_	_
78-10	15636-15638	T1	_	_
78-11	15638-15639	-	_	_
78-12	15639-15647	weighted	_	_
78-13	15648-15653	image	_	_
78-14	15654-15655	(	_	_
78-15	15655-15661	MPRAGE	_	_
78-16	15661-15662	,	_	_
78-17	15663-15665	TR	_	_
78-18	15665-15666	â€¯	_	_
78-19	15666-15667	=	_	_
78-20	15667-15668	â€¯	_	_
78-21	15668-15672	11.4	_	_
78-22	15672-15673	â€¯	_	_
78-23	15673-15675	ms	_	_
78-24	15675-15676	,	_	_
78-25	15677-15679	TE	_	_
78-26	15679-15680	â€¯	_	_
78-27	15680-15681	=	_	_
78-28	15681-15682	â€¯	_	_
78-29	15682-15685	4.4	_	_
78-30	15685-15686	â€¯	_	_
78-31	15686-15688	ms	_	_
78-32	15688-15689	,	_	_
78-33	15690-15694	flip	_	_
78-34	15695-15700	angle	_	_
78-35	15700-15701	â€¯	_	_
78-36	15701-15702	=	_	_
78-37	15702-15703	â€¯	_	_
78-38	15703-15705	10	_	_
78-39	15706-15712	degree	_	_
78-40	15712-15713	,	_	_
78-41	15714-15717	FOV	_	_
78-42	15717-15718	â€¯	_	_
78-43	15718-15719	=	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#Thing
78-44	15719-15720	â€¯	_	_
78-45	15720-15723	256	_	_
78-46	15723-15724	â€¯	_	_
78-47	15724-15725	Ã—	_	_
78-48	15725-15726	â€¯	_	_
78-49	15726-15729	256	_	_
78-50	15729-15730	,	_	_
78-51	15731-15732	1	_	_
78-52	15732-15733	â€¯	_	_
78-53	15733-15736	mm3	_	_
78-54	15737-15743	voxels	_	_
78-55	15743-15744	)	_	_
78-56	15745-15747	to	_	_
78-57	15748-15750	be	_	_
78-58	15751-15755	used	_	_
78-59	15756-15759	for	_	_
78-60	15760-15770	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	_
78-61	15771-15780	reference	_	_
78-62	15780-15781	.	_	_

79-1	15782-15785	All	_	_
79-2	15786-15796	structural	_	_
79-3	15797-15800	and	_	_
79-4	15801-15811	functional	_	_
79-5	15812-15817	image	_	_
79-6	15818-15828	processing	_	_
79-7	15829-15832	and	_	_
79-8	15833-15841	analysis	_	_
79-9	15842-15845	was	_	_
79-10	15846-15855	performed	_	_
79-11	15856-15860	with	_	_
79-12	15861-15864	the	_	_
79-13	15865-15873	Analysis	_	_
79-14	15874-15876	of	_	_
79-15	15877-15887	Functional	_	_
79-16	15888-15899	Neuroimages	_	_
79-17	15900-15901	(	_	_
79-18	15901-15905	AFNI	_	_
79-19	15905-15906	)	_	_
79-20	15907-15915	software	_	_
79-21	15916-15923	package	_	_
79-22	15923-15924	,	_	_
79-23	15925-15928	and	_	_
79-24	15929-15932	MRI	_	_
79-25	15933-15936	x-y	_	_
79-26	15937-15943	slices	_	_
79-27	15944-15948	were	_	_
79-28	15949-15962	reconstructed	_	_
79-29	15963-15967	into	_	_
79-30	15968-15972	AFNI	_	_
79-31	15973-15977	BRIK	_	_
79-32	15978-15984	format	_	_
79-33	15984-15985	.	_	_

80-1	15986-15996	Echoplanar	_	_
80-2	15997-16003	images	_	_
80-3	16004-16013	underwent	_	_
80-4	16014-16023	automatic	_	_
80-5	16024-16038	coregistration	_	_
80-6	16039-16041	to	_	_
80-7	16042-16045	the	_	_
80-8	16046-16056	anatomical	_	_
80-9	16057-16062	image	_	_
80-10	16063-16066	and	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
80-11	16067-16071	each	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
80-12	16072-16083	participant	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
80-13	16084-16091	dataset	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
80-14	16092-16095	was	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
80-15	16096-16104	visually	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
80-16	16105-16114	inspected	_	_
80-17	16115-16117	to	_	_
80-18	16118-16125	confirm	_	_
80-19	16126-16136	successful	_	_
80-20	16137-16146	alignment	_	_
80-21	16146-16147	.	_	_

81-1	16148-16155	Outlier	_	_
81-2	16156-16162	voxels	_	_
81-3	16163-16167	were	_	_
81-4	16168-16178	identified	_	_
81-5	16179-16181	in	_	_
81-6	16182-16185	the	_	_
81-7	16186-16193	aligned	_	_
81-8	16194-16200	images	_	_
81-9	16201-16206	based	_	_
81-10	16207-16209	on	_	_
81-11	16210-16217	whether	_	_
81-12	16218-16219	a	_	_
81-13	16220-16225	given	_	_
81-14	16226-16230	time	_	_
81-15	16231-16236	point	_	_
81-16	16237-16244	greatly	_	_
81-17	16245-16253	exceeded	_	_
81-18	16254-16257	the	_	_
81-19	16258-16262	mean	_	_
81-20	16263-16269	number	_	_
81-21	16270-16272	of	_	_
81-22	16273-16278	voxel	_	_
81-23	16279-16287	outliers	_	_
81-24	16288-16291	for	_	_
81-25	16292-16295	the	_	_
81-26	16296-16307	time-series	_	_
81-27	16307-16308	.	_	_

82-1	16309-16313	Time	_	_
82-2	16314-16320	points	_	_
82-3	16321-16325	with	_	_
82-4	16326-16330	high	_	_
82-5	16331-16338	numbers	_	_
82-6	16339-16341	of	_	_
82-7	16342-16349	outlier	_	_
82-8	16350-16356	voxels	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
82-9	16357-16361	were	_	_
82-10	16362-16370	excluded	_	_
82-11	16371-16375	from	_	_
82-12	16376-16386	subsequent	_	_
82-13	16387-16395	analyses	_	_
82-14	16395-16396	.	_	_

83-1	16397-16408	First-level	_	_
83-2	16409-16413	fMRI	_	_
83-3	16414-16422	analyses	_	_
83-4	16423-16425	In	_	_
83-5	16426-16427	a	_	_
83-6	16428-16433	first	_	_
83-7	16434-16441	general	_	_
83-8	16442-16448	linear	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
83-9	16449-16454	model	_	_
83-10	16455-16456	(	_	_
83-11	16456-16459	GLM	_	_
83-12	16459-16460	)	_	_
83-13	16460-16461	,	_	_
83-14	16462-16464	Go	_	_
83-15	16464-16465	,	_	_
83-16	16466-16470	Stop	_	_
83-17	16471-16478	Success	_	_
83-18	16478-16479	/	_	_
83-19	16479-16481	SS	_	_
83-20	16481-16482	,	_	_
83-21	16483-16486	and	_	_
83-22	16487-16491	Stop	_	_
83-23	16492-16497	Error	_	_
83-24	16497-16498	/	_	_
83-25	16498-16500	SE	_	_
83-26	16501-16507	trials	_	_
83-27	16508-16512	were	_	_
83-28	16513-16526	distinguished	_	_
83-29	16527-16530	and	_	_
83-30	16531-16540	convolved	_	_
83-31	16541-16545	with	_	_
83-32	16546-16547	a	_	_
83-33	16548-16557	canonical	_	_
83-34	16558-16569	hemodynamic	_	_
83-35	16570-16578	response	_	_
83-36	16579-16587	function	_	_
83-37	16588-16589	(	_	_
83-38	16589-16591	Go	_	_
83-39	16592-16597	Error	_	_
83-40	16598-16604	trials	_	_
83-41	16605-16609	were	_	_
83-42	16610-16616	scarce	_	_
83-43	16617-16620	and	_	_
83-44	16621-16624	not	_	_
83-45	16625-16633	included	_	_
83-46	16634-16636	in	_	_
83-47	16637-16642	these	_	_
83-48	16643-16651	analyses	_	_
83-49	16651-16652	)	_	_
83-50	16652-16653	.	_	_

84-1	16654-16658	Each	_	_
84-2	16659-16662	was	_	_
84-3	16663-16670	entered	_	_
84-4	16671-16673	as	_	_
84-5	16674-16678	both	_	_
84-6	16679-16690	categorical	_	_
84-7	16691-16694	and	_	_
84-8	16695-16696	P	_	_
84-9	16696-16697	(	_	_
84-10	16697-16701	stop	_	_
84-11	16701-16702	)	_	_
84-12	16702-16703	-	_	_
84-13	16703-16712	modulated	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
84-14	16713-16722	regressor	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
84-15	16723-16724	(	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
84-16	16724-16727	i.e	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
84-17	16727-16728	.	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
84-18	16728-16729	,	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
84-19	16730-16732	Go	_	_
84-20	16732-16733	,	_	_
84-21	16734-16736	SS	_	_
84-22	16736-16737	,	_	_
84-23	16738-16740	SE	_	_
84-24	16740-16741	,	_	_
84-25	16742-16747	GoxPk	_	_
84-26	16747-16748	(	_	_
84-27	16748-16752	stop	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
84-28	16752-16753	)	_	_
84-29	16753-16754	,	_	_
84-30	16755-16760	SSxPk	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
84-31	16760-16761	(	_	_
84-32	16761-16765	stop	_	_
84-33	16765-16766	)	_	_
84-34	16766-16767	,	_	_
84-35	16768-16771	and	_	_
84-36	16772-16777	SExPk	_	_
84-37	16777-16778	(	_	_
84-38	16778-16782	stop	_	_
84-39	16782-16783	)	_	_
84-40	16783-16784	)	_	_
84-41	16784-16785	.	_	_

85-1	16786-16788	To	_	_
85-2	16789-16793	more	_	_
85-3	16794-16806	specifically	_	_
85-4	16807-16814	isolate	_	_
85-5	16815-16821	neural	_	_
85-6	16822-16830	activity	_	_
85-7	16831-16838	related	_	_
85-8	16839-16841	to	_	_
85-9	16842-16848	belief	_	_
85-10	16849-16857	updating	_	_
85-11	16858-16867	processes	_	_
85-12	16868-16870	vs	_	_
85-13	16871-16882	uncertainty	_	_
85-14	16883-16891	tracking	_	_
85-15	16891-16892	,	_	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
85-16	16893-16894	a	_	_
85-17	16895-16901	second	_	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
85-18	16902-16905	GLM	_	_
85-19	16906-16909	was	_	_
85-20	16910-16917	created	_	_
85-21	16918-16922	with	_	_
85-22	16923-16926	two	_	_
85-23	16927-16932	types	_	_
85-24	16933-16935	of	_	_
85-25	16936-16946	trial-wise	_	_
85-26	16947-16955	Bayesian	_	_
85-27	16956-16966	prediction	_	_
85-28	16967-16973	errors	_	_
85-29	16974-16976	as	_	_
85-30	16977-16987	parametric	_	_
85-31	16988-16998	regressors	_	_
85-32	16998-16999	,	_	_
85-33	17000-17012	representing	_	_
85-34	17013-17016	the	_	_
85-35	17017-17028	discrepancy	_	_
85-36	17029-17036	between	_	_
85-37	17037-17045	expected	_	_
85-38	17046-17056	likelihood	_	_
85-39	17057-17059	of	_	_
85-40	17060-17066	having	_	_
85-41	17067-17069	to	_	_
85-42	17070-17074	stop	_	_
85-43	17075-17077	on	_	_
85-44	17078-17081	the	_	_
85-45	17082-17090	upcoming	_	_
85-46	17091-17096	trial	_	_
85-47	17097-17098	(	_	_
85-48	17098-17101	i.e	_	_
85-49	17101-17102	.	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
85-50	17102-17103	,	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
85-51	17104-17105	P	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
85-52	17105-17106	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
85-53	17106-17110	stop	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
85-54	17110-17111	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
85-55	17111-17112	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
85-56	17113-17116	and	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
85-57	17117-17123	actual	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
85-58	17124-17129	trial	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
85-59	17130-17134	type	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
85-60	17135-17143	observed	_	_
85-61	17144-17145	(	_	_
85-62	17145-17148	i.e	_	_
85-63	17148-17149	.	_	_
85-64	17149-17150	,	_	_
85-65	17151-17153	Go	_	_
85-66	17153-17154	â€¯	_	_
85-67	17154-17155	=	_	_
85-68	17155-17156	â€¯	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
85-69	17156-17157	0	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
85-70	17157-17158	,	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
85-71	17159-17163	Stop	_	_
85-72	17163-17164	â€¯	_	_
85-73	17164-17165	=	_	_
85-74	17165-17166	â€¯	_	_
85-75	17166-17167	1	_	_
85-76	17167-17168	)	_	_
85-77	17168-17169	.	_	_

86-1	17170-17175	These	_	_
86-2	17176-17186	regressors	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
86-3	17187-17195	included	_	_
86-4	17196-17198	in	_	_
86-5	17199-17203	this	_	_
86-6	17204-17209	order	_	_
86-7	17210-17213	the	_	_
86-8	17214-17220	signed	_	_
86-9	17221-17231	prediction	_	_
86-10	17232-17237	error	_	_
86-11	17238-17239	(	_	_
86-12	17239-17242	SPE	_	_
86-13	17242-17243	â€¯	_	_
86-14	17243-17244	=	_	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
86-15	17244-17245	â€¯	_	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
86-16	17245-17254	outcome-P	_	_
86-17	17254-17255	(	_	_
86-18	17255-17259	stop	_	_
86-19	17259-17260	)	_	_
86-20	17260-17261	â€¯	_	_
86-21	17261-17262	=	_	_
86-22	17262-17263	â€¯	_	_
86-23	17263-17268	sk-Pk	_	_
86-24	17268-17269	(	_	_
86-25	17269-17273	stop	_	_
86-26	17273-17274	)	_	_
86-27	17274-17275	)	_	_
86-28	17276-17279	and	_	_
86-29	17280-17283	the	_	_
86-30	17284-17292	unsigned	_	_
86-31	17293-17303	prediction	_	_
86-32	17304-17309	error	_	_
86-33	17310-17311	(	_	_
86-34	17311-17314	UPE	_	_
86-35	17314-17315	â€¯	_	_
86-36	17315-17316	=	_	_
86-37	17316-17317	â€¯	_	_
86-38	17317-17318	|	_	_
86-39	17318-17328	outcome-Pk	_	_
86-40	17328-17329	(	_	_
86-41	17329-17333	stop	_	_
86-42	17333-17334	)	_	_
86-43	17334-17335	|	_	_
86-44	17335-17336	â€¯	_	_
86-45	17336-17337	=	_	_
86-46	17337-17338	â€¯	_	_
86-47	17338-17339	|	_	_
86-48	17339-17344	sk-Pk	_	_
86-49	17344-17345	(	_	_
86-50	17345-17349	stop	_	_
86-51	17349-17350	)	_	_
86-52	17350-17351	|	_	_
86-53	17351-17352	;	_	_
86-54	17353-17356	see	_	_
86-55	17357-17360	Fig	_	_
86-56	17360-17361	.	_	_
86-57	17362-17364	1A	_	_
86-58	17364-17365	,	_	_
86-59	17366-17372	bottom	_	_
86-60	17372-17373	)	_	_
86-61	17373-17374	,	_	_
86-62	17375-17377	as	_	_
86-63	17378-17382	well	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
86-64	17383-17385	as	_	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
86-65	17386-17391	trial	_	_
86-66	17392-17397	error	_	_
86-67	17398-17399	(	_	_
86-68	17399-17400	0	_	_
86-69	17400-17401	â€¯	_	_
86-70	17401-17402	=	_	_
86-71	17402-17403	â€¯	_	_
86-72	17403-17410	correct	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
86-73	17411-17413	or	_	_
86-74	17414-17415	1	_	_
86-75	17415-17416	â€¯	_	_
86-76	17416-17417	=	_	_
86-77	17417-17418	â€¯	_	_
86-78	17418-17423	error	_	_
86-79	17423-17424	)	_	_
86-80	17425-17427	to	_	_
86-81	17428-17435	control	_	_
86-82	17436-17439	for	_	_
86-83	17440-17451	performance	_	_
86-84	17452-17457	error	_	_
86-85	17458-17465	related	_	_
86-86	17466-17474	activity	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
86-87	17474-17475	.	_	_

87-1	17476-17480	Each	_	_
87-2	17481-17483	of	_	_
87-3	17484-17489	these	_	_
87-4	17490-17500	regressors	_	_
87-5	17501-17505	were	_	_
87-6	17506-17520	orthogonalized	_	_
87-7	17521-17525	with	_	_
87-8	17526-17533	respect	_	_
87-9	17534-17536	to	_	_
87-10	17537-17540	the	_	_
87-11	17541-17550	preceding	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
87-12	17551-17554	one	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
87-13	17555-17560	given	_	_
87-14	17561-17564	the	_	_
87-15	17565-17576	non-trivial	_	_
87-16	17577-17589	collinearity	_	_
87-17	17590-17597	between	_	_
87-18	17598-17602	them	_	_
87-19	17602-17603	.	_	_

88-1	17604-17608	Both	_	_
88-2	17609-17613	GLMs	_	_
88-3	17614-17622	included	_	_
88-4	17623-17626	the	_	_
88-5	17627-17636	following	_	_
88-6	17637-17647	regressors	_	_
88-7	17648-17650	of	_	_
88-8	17651-17662	no-interest	_	_
88-9	17662-17663	:	_	_
88-10	17664-17665	a	_	_
88-11	17666-17674	baseline	_	_
88-12	17675-17684	regressor	_	_
88-13	17685-17686	(	_	_
88-14	17686-17697	inter-trial	_	_
88-15	17698-17707	intervals	_	_
88-16	17707-17708	)	_	_
88-17	17708-17709	,	_	_
88-18	17710-17715	three	_	_
88-19	17716-17722	linear	_	_
88-20	17723-17728	drift	_	_
88-21	17729-17739	regressors	_	_
88-22	17740-17741	(	_	_
88-23	17741-17742	x	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
88-24	17742-17743	,	_	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
88-25	17743-17744	y	_	_
88-26	17744-17745	,	_	_
88-27	17745-17746	z	_	_
88-28	17746-17747	)	_	_
88-29	17747-17748	,	_	_
88-30	17749-17752	and	_	_
88-31	17753-17758	three	_	_
88-32	17759-17765	motion	_	_
88-33	17766-17776	regressors	_	_
88-34	17777-17778	(	_	_
88-35	17778-17783	pitch	_	_
88-36	17783-17784	,	_	_
88-37	17785-17788	yaw	_	_
88-38	17788-17789	,	_	_
88-39	17790-17794	roll	_	_
88-40	17794-17795	)	_	_
88-41	17795-17796	,	_	_
88-42	17797-17800	and	_	_
88-43	17801-17803	Go	_	_
88-44	17804-17807	RTs	_	_
88-45	17808-17809	(	_	_
88-46	17809-17821	residualized	_	_
88-47	17822-17826	with	_	_
88-48	17827-17834	respect	_	_
88-49	17835-17837	to	_	_
88-50	17838-17839	P	_	_
88-51	17839-17840	(	_	_
88-52	17840-17844	stop	_	_
88-53	17844-17845	)	_	_
88-54	17845-17846	)	_	_
88-55	17847-17849	to	_	_
88-56	17850-17857	control	_	_
88-57	17858-17861	for	_	_
88-58	17862-17867	motor	_	_
88-59	17868-17876	response	_	_
88-60	17877-17886	confounds	_	_
88-61	17886-17887	.	_	_

89-1	17888-17894	Images	_	_
89-2	17895-17899	were	_	_
89-3	17900-17909	spatially	_	_
89-4	17910-17918	filtered	_	_
89-5	17919-17920	(	_	_
89-6	17920-17928	Gaussian	_	_
89-7	17929-17933	full	_	_
89-8	17934-17939	width	_	_
89-9	17940-17944	half	_	_
89-10	17945-17952	maximum	_	_
89-11	17953-17954	4	_	_
89-12	17954-17955	â€¯	_	_
89-13	17955-17957	mm	_	_
89-14	17957-17958	)	_	_
89-15	17959-17961	to	_	_
89-16	17962-17969	account	_	_
89-17	17970-17973	for	_	_
89-18	17974-17984	individual	_	_
89-19	17985-17995	anatomical	_	_
89-20	17996-18007	differences	_	_
89-21	18007-18008	.	_	_

90-1	18009-18018	Automated	_	_
90-2	18019-18028	Talairach	_	_
90-3	18029-18044	transformations	_	_
90-4	18045-18049	were	_	_
90-5	18050-18057	applied	_	_
90-6	18058-18060	to	_	_
90-7	18061-18071	anatomical	_	_
90-8	18072-18078	images	_	_
90-9	18079-18082	and	_	_
90-10	18083-18093	functional	_	_
90-11	18094-18100	images	_	_
90-12	18101-18105	were	_	_
90-13	18106-18118	subsequently	_	_
90-14	18119-18130	transformed	_	_
90-15	18131-18135	into	_	_
90-16	18136-18145	Talairach	_	_
90-17	18146-18151	space	_	_
90-18	18151-18152	.	_	_

91-1	18153-18160	Percent	_	_
91-2	18161-18167	signal	_	_
91-3	18168-18174	change	_	_
91-4	18175-18176	(	_	_
91-5	18176-18177	%	_	_
91-6	18177-18179	SC	_	_
91-7	18179-18180	)	_	_
91-8	18181-18184	was	_	_
91-9	18185-18195	determined	_	_
91-10	18196-18198	by	_	_
91-11	18199-18207	dividing	_	_
91-12	18208-18211	the	_	_
91-13	18212-18218	signal	_	_
91-14	18219-18222	for	_	_
91-15	18223-18227	each	_	_
91-16	18228-18237	regressor	_	_
91-17	18238-18240	of	_	_
91-18	18241-18249	interest	_	_
91-19	18250-18252	by	_	_
91-20	18253-18256	the	_	_
91-21	18257-18265	baseline	_	_
91-22	18266-18275	regressor	_	_
91-23	18275-18276	.	_	_

92-1	18277-18289	Second-level	_	_
92-2	18290-18298	analyses	_	_
92-3	18299-18301	At	_	_
92-4	18302-18305	the	_	_
92-5	18306-18321	between-subject	_	_
92-6	18322-18327	level	_	_
92-7	18327-18328	,	_	_
92-8	18329-18332	two	_	_
92-9	18333-18338	types	_	_
92-10	18339-18341	of	_	_
92-11	18342-18351	voxelwise	_	_
92-12	18352-18365	mixed-effects	_	_
92-13	18366-18372	linear	_	_
92-14	18373-18379	models	_	_
92-15	18380-18381	(	_	_
92-16	18381-18384	LME	_	_
92-17	18384-18385	)	_	_
92-18	18386-18390	were	_	_
92-19	18391-18394	fit	_	_
92-20	18395-18397	to	_	_
92-21	18398-18401	the	_	_
92-22	18402-18414	coefficients	_	_
92-23	18415-18417	of	_	_
92-24	18418-18421	our	_	_
92-25	18422-18433	first-level	_	_
92-26	18434-18437	GLM	_	_
92-27	18437-18438	.	_	_

93-1	18439-18441	In	_	_
93-2	18442-18445	the	_	_
93-3	18446-18451	first	_	_
93-4	18452-18455	LME	_	_
93-5	18455-18456	,	_	_
93-6	18457-18459	we	_	_
93-7	18460-18465	first	_	_
93-8	18466-18472	tested	_	_
93-9	18473-18476	for	_	_
93-10	18477-18480	the	_	_
93-11	18481-18492	interaction	_	_
93-12	18493-18495	of	_	_
93-13	18496-18504	clinical	_	_
93-14	18505-18511	status	_	_
93-15	18512-18513	(	_	_
93-16	18513-18522	abstinent	_	_
93-17	18523-18525	vs	_	_
93-18	18526-18534	relapsed	_	_
93-19	18534-18535	)	_	_
93-20	18536-18539	and	_	_
93-21	18540-18550	modulation	_	_
93-22	18551-18553	of	_	_
93-23	18554-18555	P	_	_
93-24	18555-18556	(	_	_
93-25	18556-18560	Stop	_	_
93-26	18560-18561	)	_	_
93-27	18562-18567	under	_	_
93-28	18568-18572	each	_	_
93-29	18573-18575	Go	_	_
93-30	18576-18578	vs	_	_
93-31	18579-18583	Stop	_	_
93-32	18584-18590	trials	_	_
93-33	18591-18592	(	_	_
93-34	18592-18595	i.e	_	_
93-35	18595-18596	,	_	_
93-36	18597-18601	GoxP	_	_
93-37	18601-18602	(	_	_
93-38	18602-18606	stop	_	_
93-39	18606-18607	)	_	_
93-40	18608-18610	vs	_	_
93-41	18611-18618	StopxPk	_	_
93-42	18618-18619	(	_	_
93-43	18619-18623	stop	_	_
93-44	18623-18624	)	_	_
93-45	18624-18625	,	_	_
93-46	18626-18628	SS	_	_
93-47	18629-18632	and	_	_
93-48	18633-18635	SE	_	_
93-49	18636-18640	were	_	_
93-50	18641-18649	averaged	_	_
93-51	18649-18650	)	_	_
93-52	18650-18651	,	_	_
93-53	18652-18656	with	_	_
93-54	18657-18664	subject	_	_
93-55	18665-18672	treated	_	_
93-56	18673-18675	as	_	_
93-57	18676-18682	random	_	_
93-58	18683-18692	intercept	_	_
93-59	18693-18699	effect	_	_
93-60	18699-18700	.	_	_

94-1	18701-18706	Whole	_	_
94-2	18707-18712	brain	_	_
94-3	18713-18724	statistical	_	_
94-4	18725-18729	maps	_	_
94-5	18730-18734	were	_	_
94-6	18735-18743	obtained	_	_
94-7	18744-18747	for	_	_
94-8	18748-18751	the	_	_
94-9	18752-18757	group	_	_
94-10	18758-18762	main	_	_
94-11	18763-18769	effect	_	_
94-12	18770-18771	(	_	_
94-13	18771-18781	reflecting	_	_
94-14	18782-18787	areas	_	_
94-15	18788-18796	tracking	_	_
94-16	18797-18798	a	_	_
94-17	18799-18807	clinical	_	_
94-18	18808-18814	status	_	_
94-19	18815-18820	group	_	_
94-20	18821-18831	difference	_	_
94-21	18832-18834	in	_	_
94-22	18835-18840	prior	_	_
94-23	18841-18842	P	_	_
94-24	18842-18843	(	_	_
94-25	18843-18847	stop	_	_
94-26	18847-18848	)	_	_
94-27	18849-18854	value	_	_
94-28	18855-18867	irrespective	_	_
94-29	18868-18870	of	_	_
94-30	18871-18876	trial	_	_
94-31	18877-18881	type	_	_
94-32	18881-18882	)	_	_
94-33	18883-18886	and	_	_
94-34	18887-18890	the	_	_
94-35	18891-18899	clinical	_	_
94-36	18900-18906	status	_	_
94-37	18907-18908	X	_	_
94-38	18909-18910	P	_	_
94-39	18910-18911	(	_	_
94-40	18911-18915	stop	_	_
94-41	18915-18916	)	_	_
94-42	18917-18926	modulated	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
94-43	18927-18932	trial	_	_
94-44	18933-18937	type	_	_
94-45	18938-18949	interaction	_	_
94-46	18949-18950	.	_	_

95-1	18951-18953	In	_	_
95-2	18954-18959	order	_	_
95-3	18960-18962	to	_	_
95-4	18963-18969	assess	_	_
95-5	18970-18973	for	_	_
95-6	18974-18983	potential	_	_
95-7	18984-18989	group	_	_
95-8	18990-19000	difference	_	_
95-9	19001-19003	in	_	_
95-10	19004-19007	the	_	_
95-11	19008-19018	modulation	_	_
95-12	19019-19021	of	_	_
95-13	19022-19027	trial	_	_
95-14	19028-19036	accuracy	_	_
95-15	19037-19038	(	_	_
95-16	19038-19041	i.e	_	_
95-17	19041-19042	.	_	_
95-18	19042-19043	,	_	_
95-19	19044-19054	successful	_	_
95-20	19055-19057	vs	_	_
95-21	19058-19064	failed	_	_
95-22	19065-19075	inhibition	_	_
95-23	19075-19076	)	_	_
95-24	19077-19079	by	_	_
95-25	19080-19081	P	_	_
95-26	19081-19082	(	_	_
95-27	19082-19086	stop	_	_
95-28	19086-19087	)	_	_
95-29	19087-19088	,	_	_
95-30	19089-19090	a	_	_
95-31	19091-19098	similar	_	_
95-32	19099-19102	LME	_	_
95-33	19103-19111	approach	_	_
95-34	19112-19115	was	_	_
95-35	19116-19120	used	_	_
95-36	19120-19121	.	_	_

96-1	19122-19134	Specifically	_	_
96-2	19134-19135	,	_	_
96-3	19136-19138	we	_	_
96-4	19139-19147	obtained	_	_
96-5	19148-19159	statistical	_	_
96-6	19160-19164	maps	_	_
96-7	19165-19168	for	_	_
96-8	19169-19172	the	_	_
96-9	19173-19177	main	_	_
96-10	19178-19184	effect	_	_
96-11	19185-19187	of	_	_
96-12	19188-19196	clinical	_	_
96-13	19197-19203	status	_	_
96-14	19204-19205	(	_	_
96-15	19205-19215	reflecting	_	_
96-16	19216-19225	potential	_	_
96-17	19226-19231	group	_	_
96-18	19232-19242	difference	_	_
96-19	19243-19245	in	_	_
96-20	19246-19247	P	_	_
96-21	19247-19248	(	_	_
96-22	19248-19252	stop	_	_
96-23	19252-19253	)	_	_
96-24	19254-19264	activation	_	_
96-25	19265-19267	on	_	_
96-26	19268-19272	Stop	_	_
96-27	19273-19279	trials	_	_
96-28	19280-19292	irrespective	_	_
96-29	19293-19295	of	_	_
96-30	19296-19304	accuracy	_	_
96-31	19304-19305	)	_	_
96-32	19306-19309	and	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
96-33	19310-19313	for	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
96-34	19314-19317	the	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
96-35	19318-19326	clinical	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
96-36	19327-19333	status	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomeryâ€“AsbergDepressionRatingScale
96-37	19334-19335	X	_	_
96-38	19336-19337	P	_	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
96-39	19337-19338	(	_	_
96-40	19338-19342	stop	_	_
96-41	19342-19343	)	_	_
96-42	19344-19353	modulated	_	_
96-43	19354-19359	trial	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
96-44	19360-19364	type	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
96-45	19365-19366	(	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
96-46	19366-19368	SE	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
96-47	19369-19371	vs	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
96-48	19372-19374	SS	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
96-49	19374-19375	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
96-50	19376-19387	interaction	_	_
96-51	19387-19388	.	_	_

97-1	19389-19391	To	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#Thing
97-2	19392-19399	correct	_	_
97-3	19400-19403	for	_	_
97-4	19404-19412	multiple	_	_
97-5	19413-19424	comparisons	_	_
97-6	19424-19425	,	_	_
97-7	19426-19428	we	_	_
97-8	19429-19433	used	_	_
97-9	19434-19435	a	_	_
97-10	19436-19443	cluster	_	_
97-11	19444-19453	threshold	_	_
97-12	19454-19464	adjustment	_	_
97-13	19465-19470	based	_	_
97-14	19471-19473	on	_	_
97-15	19474-19479	Monte	_	_
97-16	19480-19485	Carlo	_	_
97-17	19486-19497	simulations	_	_
97-18	19498-19499	(	_	_
97-19	19499-19508	generated	_	_
97-20	19509-19513	with	_	_
97-21	19514-19520	AFNI's	_	_
97-22	19521-19531	3dClustSim	_	_
97-23	19532-19539	program	_	_
97-24	19539-19540	)	_	_
97-25	19540-19541	.	_	_

98-1	19542-19544	We	_	_
98-2	19545-19550	first	_	_
98-3	19551-19561	calculated	_	_
98-4	19562-19569	spatial	_	_
98-5	19570-19585	autocorrelation	_	_
98-6	19586-19594	function	_	_
98-7	19595-19596	(	_	_
98-8	19596-19599	acf	_	_
98-9	19599-19600	)	_	_
98-10	19601-19611	parameters	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
98-11	19612-19616	from	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
98-12	19617-19620	the	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
98-13	19621-19624	1st	_	_
98-14	19625-19628	glm	_	_
98-15	19629-19634	model	_	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
98-16	19635-19644	residuals	_	_
98-17	19644-19645	,	_	_
98-18	19646-19651	using	_	_
98-19	19652-19655	the	_	_
98-20	19656-19663	3dFHWMx	_	_
98-21	19664-19672	function	_	_
98-22	19673-19674	(	_	_
98-23	19674-19679	which	_	_
98-24	19680-19684	does	_	_
98-25	19685-19688	not	_	_
98-26	19689-19695	assume	_	_
98-27	19696-19697	a	_	_
98-28	19698-19704	purely	_	_
98-29	19705-19713	Gaussian	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
98-30	19714-19717	acf	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
98-31	19718-19726	function	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
98-32	19726-19727	,	_	_
98-33	19728-19731	but	_	_
98-34	19732-19738	rather	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
98-35	19739-19740	a	_	_
98-36	19741-19748	mixture	_	_
98-37	19749-19751	of	_	_
98-38	19752-19760	Gaussian	_	_
98-39	19761-19764	and	_	_
98-40	19765-19781	mono-exponential	_	_
98-41	19781-19782	)	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
98-42	19782-19783	.	_	_

99-1	19784-19787	The	_	_
99-2	19788-19796	obtained	_	_
99-3	19797-19807	parameters	_	_
99-4	19807-19808	,	_	_
99-5	19809-19817	averaged	_	_
99-6	19818-19824	across	_	_
99-7	19825-19837	participants	_	_
99-8	19837-19838	,	_	_
99-9	19839-19843	were	_	_
99-10	19844-19847	fed	_	_
99-11	19848-19850	to	_	_
99-12	19851-19854	the	_	_
99-13	19855-19865	3dClustSim	_	_
99-14	19866-19874	function	_	_
99-15	19875-19877	to	_	_
99-16	19878-19887	determine	_	_
99-17	19888-19892	FWER	_	_
99-18	19893-19902	corrected	_	_
99-19	19903-19910	cluster	_	_
99-20	19911-19915	size	_	_
99-21	19915-19916	.	_	_

100-1	19917-19922	Based	_	_
100-2	19923-19925	on	_	_
100-3	19926-19929	the	_	_
100-4	19930-19941	simulations	_	_
100-5	19941-19942	,	_	_
100-6	19943-19944	a	_	_
100-7	19945-19952	minimum	_	_
100-8	19953-19960	cluster	_	_
100-9	19961-19967	volume	_	_
100-10	19968-19970	of	_	_
100-11	19971-19974	896	_	_
100-12	19974-19975	â€¯	_	_
100-13	19975-19977	Î¼L	_	_
100-14	19978-19981	was	_	_
100-15	19982-19987	found	_	_
100-16	19988-19990	to	_	_
100-17	19991-19993	be	_	_
100-18	19994-20004	sufficient	_	_
100-19	20005-20007	to	_	_
100-20	20008-20015	correct	_	_
100-21	20016-20019	for	_	_
100-22	20020-20028	multiple	_	_
100-23	20029-20040	comparisons	_	_
100-24	20041-20043	at	_	_
100-25	20044-20048	FWER	_	_
100-26	20048-20049	â€¯	_	_
100-27	20049-20050	=	_	_
100-28	20050-20051	â€¯	_	_
100-29	20051-20052	p	_	_
100-30	20052-20053	â€¯	_	_
100-31	20053-20054	<	_	_
100-32	20054-20055	â€¯	_	_
100-33	20055-20058	.05	_	_
100-34	20059-20063	with	_	_
100-35	20064-20065	a	_	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
100-36	20066-20073	minimum	_	_
100-37	20074-20083	voxelwise	_	_
100-38	20084-20095	significant	_	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
100-39	20096-20105	threshold	_	_
100-40	20106-20108	of	_	_
100-41	20109-20110	p	_	_
100-42	20110-20111	â€¯	_	_
100-43	20111-20112	<	_	_
100-44	20112-20113	â€¯	_	_
100-45	20113-20117	.005	_	_
100-46	20117-20118	.	_	_

101-1	20119-20124	While	_	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
101-2	20125-20129	less	_	_
101-3	20130-20142	conservative	_	_
101-4	20143-20147	than	_	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
101-5	20148-20153	using	_	_
101-6	20154-20155	a	_	_
101-7	20156-20157	p	_	_
101-8	20157-20158	â€¯	_	_
101-9	20158-20159	<	_	_
101-10	20159-20160	â€¯	_	_
101-11	20160-20164	.001	_	_
101-12	20165-20167	or	_	_
101-13	20168-20169	p	_	_
101-14	20169-20170	â€¯	_	_
101-15	20170-20171	<	_	_
101-16	20171-20172	â€¯	_	_
101-17	20172-20176	.002	_	_
101-18	20177-20186	voxelwise	_	_
101-19	20187-20196	threshold	_	_
101-20	20196-20197	,	_	_
101-21	20198-20202	this	_	_
101-22	20203-20210	setting	_	_
101-23	20211-20219	provides	_	_
101-24	20220-20221	a	_	_
101-25	20222-20229	balance	_	_
101-26	20230-20232	of	_	http://maven.renci.org/NeuroBridge/neurobridge#Age
101-27	20233-20241	adequate	_	_
101-28	20242-20252	correction	_	_
101-29	20253-20256	for	_	_
101-30	20257-20265	multiple	_	_
101-31	20266-20277	comparisons	_	_
101-32	20278-20283	while	_	_
101-33	20284-20292	ensuring	_	_
101-34	20293-20294	a	_	_
101-35	20295-20306	substantial	_	_
101-36	20307-20314	minimum	_	_
101-37	20315-20322	cluster	_	_
101-38	20323-20327	size	_	_
101-39	20327-20328	.	_	_

102-1	20329-20331	We	_	_
102-2	20332-20336	also	_	_
102-3	20337-20341	note	_	_
102-4	20342-20346	that	_	_
102-5	20347-20351	this	_	_
102-6	20352-20361	threshold	_	_
102-7	20362-20364	is	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
102-8	20365-20370	still	_	_
102-9	20371-20381	relatively	_	_
102-10	20382-20394	conservative	_	_
102-11	20395-20397	in	_	_
102-12	20398-20403	light	_	_
102-13	20404-20406	of	_	_
102-14	20407-20415	previous	_	_
102-15	20416-20420	work	_	_
102-16	20421-20427	having	_	_
102-17	20428-20435	applied	_	_
102-18	20436-20440	this	_	_
102-19	20441-20449	Bayesian	_	_
102-20	20450-20463	computational	_	_
102-21	20464-20469	model	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
102-22	20470-20472	in	_	_
102-23	20473-20480	similar	_	_
102-24	20481-20492	populations	_	_
102-25	20493-20496	and	_	_
102-26	20497-20509	experimental	_	_
102-27	20510-20518	settings	_	_
102-28	20518-20519	,	_	_
102-29	20520-20525	which	_	_
102-30	20526-20531	would	_	_
102-31	20532-20539	provide	_	_
102-32	20540-20547	grounds	_	_
102-33	20548-20551	for	_	_
102-34	20552-20553	a	_	_
102-35	20554-20558	more	_	_
102-36	20559-20566	focused	_	_
102-37	20567-20573	search	_	_
102-38	20574-20580	within	_	_
102-39	20581-20584	the	_	_
102-40	20585-20590	brain	_	_
102-41	20591-20596	based	_	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
102-42	20597-20599	on	_	_
102-43	20600-20607	regions	_	_
102-44	20608-20610	of	_	_
102-45	20611-20619	interest	_	_
102-46	20619-20620	.	_	_

103-1	20621-20628	Finally	_	_
103-2	20628-20629	,	_	_
103-3	20630-20636	within	_	_
103-4	20637-20640	the	_	_
103-5	20641-20648	regions	_	_
103-6	20649-20659	identified	_	_
103-7	20660-20664	with	_	_
103-8	20665-20670	those	_	_
103-9	20671-20675	LMEs	_	_
103-10	20675-20676	,	_	_
103-11	20677-20679	we	_	_
103-12	20680-20690	identified	_	_
103-13	20691-20696	those	_	_
103-14	20697-20701	that	_	_
103-15	20702-20706	were	_	_
103-16	20707-20717	consistent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
103-17	20718-20722	with	_	_
103-18	20723-20724	a	_	_
103-19	20725-20734	potential	_	_
103-20	20735-20740	group	_	_
103-21	20741-20751	difference	_	_
103-22	20752-20754	in	_	_
103-23	20755-20761	either	_	_
103-24	20762-20766	type	_	_
103-25	20767-20769	of	_	_
103-26	20770-20778	Bayesian	_	_
103-27	20779-20789	prediction	_	_
103-28	20790-20796	errors	_	_
103-29	20797-20798	(	_	_
103-30	20798-20801	UPE	_	_
103-31	20802-20804	or	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
103-32	20805-20808	SPE	_	_
103-33	20808-20809	)	_	_
103-34	20809-20810	,	_	_
103-35	20811-20816	using	_	_
103-36	20817-20820	our	_	_
103-37	20821-20827	second	_	_
103-38	20828-20831	GLM	_	_
103-39	20832-20835	for	_	_
103-40	20836-20843	regions	_	_
103-41	20844-20846	of	_	_
103-42	20847-20855	interest	_	_
103-43	20856-20857	(	_	_
103-44	20857-20860	ROI	_	_
103-45	20860-20861	)	_	_
103-46	20862-20870	analyses	_	_
103-47	20870-20871	.	_	_

104-1	20872-20880	Moreover	_	_
104-2	20880-20881	,	_	_
104-3	20882-20885	for	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
104-4	20886-20893	regions	_	_
104-5	20894-20904	consistent	_	_
104-6	20905-20909	with	_	_
104-7	20910-20911	a	_	_
104-8	20912-20917	group	_	_
104-9	20918-20922	main	_	_
104-10	20923-20929	effect	_	_
104-11	20930-20932	or	_	_
104-12	20933-20938	group	_	_
104-13	20939-20940	X	_	_
104-14	20941-20946	trial	_	_
104-15	20947-20951	type	_	_
104-16	20952-20963	interaction	_	_
104-17	20963-20964	,	_	_
104-18	20965-20967	we	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
104-19	20968-20980	specifically	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
104-20	20981-20988	checked	_	_
104-21	20989-20992	for	_	_
104-22	20993-21004	convergence	_	_
104-23	21005-21012	between	_	_
104-24	21013-21020	results	_	_
104-25	21021-21025	from	_	_
104-26	21026-21029	the	_	_
104-27	21030-21036	second	_	_
104-28	21037-21040	GLM	_	_
104-29	21041-21044	and	_	_
104-30	21045-21048	the	_	_
104-31	21049-21056	pattern	_	_
104-32	21057-21059	of	_	_
104-33	21060-21070	activation	_	_
104-34	21071-21073	to	_	_
104-35	21074-21075	P	_	_
104-36	21075-21076	(	_	_
104-37	21076-21080	Stop	_	_
104-38	21080-21081	)	_	_
104-39	21082-21084	as	_	_
104-40	21085-21093	function	_	_
104-41	21094-21096	of	_	_
104-42	21097-21102	trial	_	_
104-43	21103-21107	type	_	_
104-44	21108-21109	(	_	_
104-45	21109-21114	first	_	_
104-46	21115-21118	GLM	_	_
104-47	21118-21119	)	_	_
104-48	21119-21120	.	_	_

105-1	21121-21133	Specifically	_	_
105-2	21133-21134	,	_	_
105-3	21135-21142	regions	_	_
105-4	21143-21147	with	_	_
105-5	21148-21156	non-zero	_	_
105-6	21157-21158	P	_	_
105-7	21158-21159	(	_	_
105-8	21159-21163	stop	_	_
105-9	21163-21164	)	_	_
105-10	21165-21176	activations	_	_
105-11	21177-21179	of	_	_
105-12	21180-21188	opposite	_	_
105-13	21189-21194	signs	_	_
105-14	21195-21197	or	_	_
105-15	21198-21202	with	_	_
105-16	21203-21206	the	_	_
105-17	21207-21211	same	_	_
105-18	21212-21217	signs	_	_
105-19	21218-21224	across	_	_
105-20	21225-21227	Go	_	_
105-21	21228-21231	and	_	_
105-22	21232-21236	Stop	_	_
105-23	21237-21243	trials	_	_
105-24	21243-21244	,	_	_
105-25	21245-21251	should	_	_
105-26	21252-21254	be	_	_
105-27	21255-21265	consistent	_	_
105-28	21266-21270	with	_	_
105-29	21271-21272	a	_	_
105-30	21273-21284	significant	_	_
105-31	21285-21290	group	_	_
105-32	21291-21301	difference	_	_
105-33	21302-21304	in	_	_
105-34	21305-21308	UPE	_	_
105-35	21309-21312	and	_	_
105-36	21313-21316	SPE	_	_
105-37	21317-21328	activations	_	_
105-38	21328-21329	,	_	_
105-39	21330-21342	respectively	_	_
105-40	21342-21343	.	_	_

106-1	21344-21348	This	_	_
106-2	21349-21351	is	_	_
106-3	21352-21359	because	_	_
106-4	21360-21362	an	_	_
106-5	21363-21366	SPE	_	_
106-6	21367-21369	is	_	_
106-7	21370-21375	equal	_	_
106-8	21376-21378	to	_	_
106-9	21379-21380	0	_	_
106-10	21381-21382	-	_	_
106-11	21383-21384	P	_	_
106-12	21384-21385	(	_	_
106-13	21385-21389	stop	_	_
106-14	21389-21390	)	_	_
106-15	21390-21391	â€¯	_	_
106-16	21391-21392	=	_	_
106-17	21392-21393	â€¯	_	_
106-18	21393-21394	âˆ’	_	_
106-19	21395-21396	P	_	_
106-20	21396-21397	(	_	_
106-21	21397-21401	stop	_	_
106-22	21401-21402	)	_	_
106-23	21403-21405	on	_	_
106-24	21406-21408	Go	_	_
106-25	21409-21415	trials	_	_
106-26	21415-21416	,	_	_
106-27	21417-21420	and	_	_
106-28	21421-21424	SPE	_	_
106-29	21424-21425	â€¯	_	_
106-30	21425-21426	=	_	_
106-31	21426-21427	â€¯	_	_
106-32	21427-21428	1	_	_
106-33	21429-21430	â€“	_	_
106-34	21431-21432	P	_	_
106-35	21432-21433	(	_	_
106-36	21433-21437	stop	_	_
106-37	21437-21438	)	_	_
106-38	21439-21441	on	_	_
106-39	21442-21446	Stop	_	_
106-40	21447-21453	trials	_	_
106-41	21453-21454	,	_	_
106-42	21455-21458	and	_	_
106-43	21459-21463	thus	_	_
106-44	21464-21474	negatively	_	_
106-45	21475-21485	correlated	_	_
106-46	21486-21490	with	_	_
106-47	21491-21492	P	_	_
106-48	21492-21493	(	_	_
106-49	21493-21497	stop	_	_
106-50	21497-21498	)	_	_
106-51	21499-21501	on	_	_
106-52	21502-21506	both	_	_
106-53	21507-21511	type	_	_
106-54	21512-21514	of	_	_
106-55	21515-21521	trials	_	_
106-56	21521-21522	.	_	_

107-1	21523-21525	In	_	_
107-2	21526-21534	contrast	_	_
107-3	21534-21535	,	_	_
107-4	21536-21539	UPE	_	_
107-5	21540-21542	is	_	_
107-6	21543-21548	equal	_	_
107-7	21549-21551	to	_	_
107-8	21552-21553	|	_	_
107-9	21553-21554	0	_	_
107-10	21555-21556	-	_	_
107-11	21557-21558	P	_	_
107-12	21558-21559	(	_	_
107-13	21559-21563	stop	_	_
107-14	21563-21564	)	_	_
107-15	21564-21565	|	_	_
107-16	21565-21566	â€¯	_	_
107-17	21566-21567	=	_	_
107-18	21567-21568	â€¯	_	_
107-19	21568-21569	P	_	_
107-20	21569-21570	(	_	_
107-21	21570-21574	stop	_	_
107-22	21574-21575	)	_	_
107-23	21576-21578	on	_	_
107-24	21579-21581	Go	_	_
107-25	21582-21588	trials	_	_
107-26	21589-21592	and	_	_
107-27	21593-21595	to	_	_
107-28	21596-21597	|	_	_
107-29	21597-21598	1	_	_
107-30	21599-21600	-	_	_
107-31	21601-21602	P	_	_
107-32	21602-21603	(	_	_
107-33	21603-21607	stop	_	_
107-34	21607-21608	)	_	_
107-35	21608-21609	|	_	_
107-36	21609-21610	â€¯	_	_
107-37	21610-21611	=	_	_
107-38	21611-21612	â€¯	_	_
107-39	21612-21613	1	_	_
107-40	21614-21615	â€“	_	_
107-41	21616-21617	P	_	_
107-42	21617-21618	(	_	_
107-43	21618-21622	stop	_	_
107-44	21622-21623	)	_	_
107-45	21624-21626	on	_	_
107-46	21627-21631	Stop	_	_
107-47	21632-21638	trials	_	_
107-48	21638-21639	,	_	_
107-49	21640-21643	and	_	_
107-50	21644-21648	thus	_	_
107-51	21649-21655	should	_	_
107-52	21656-21658	be	_	_
107-53	21659-21669	positively	_	_
107-54	21670-21680	correlated	_	_
107-55	21681-21683	on	_	_
107-56	21684-21686	Go	_	_
107-57	21687-21693	trials	_	_
107-58	21694-21697	but	_	_
107-59	21698-21708	negatively	_	_
107-60	21709-21719	correlated	_	_
107-61	21720-21724	with	_	_
107-62	21725-21726	P	_	_
107-63	21726-21727	(	_	_
107-64	21727-21731	stop	_	_
107-65	21731-21732	)	_	_
107-66	21733-21735	on	_	_
107-67	21736-21740	Stop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
107-68	21741-21747	trials	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
107-69	21748-21749	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
107-70	21749-21752	see	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
107-71	21752-21753	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging















































































































